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The liver differs from other solid organs in that it has a dual blood supply, receiving arterial 
blood via the hepatic artery and venous blood via the portal vein . The reperfusion injury 
which occurs after ischemia, has been studied to only a limited extent in the liver. In 
particular, the relative contribution of the portal venous blood and the hepatic arterial blood to 
the reperfusion injury has not been documented previously. 
During liver transplantation , implantation of the new liver is achieved by anastomosing the 
suprahepatic vena cava, the infrahepatic vena cava and the portal vein . At this stage, the 
liver is reperfused with portal venous blood only. Thereafter the hepatic arterial anastomosis 
is undertaken. The delay in providing the liver allograft with arterial blood will depend upon 
the difficulty in the dissection of the hepatic artery. The impact of the delay in rearterialization 
of the liver allograft has not been studied previously. 
Currently, the University of Wisconsin Solution is the gold standard for liver preservation. 
Celsior is a new cardioplegic solution , which has also been suggested for use for liver 
preservation. However, its role as a liver preservation solution has been studied to a limited 
extent. 
The aim of this study was: 
1. To document the reperfusion injury after liver transplantation. 
2. To document the relative contribution of the portal venous blood and the hepatic 
arterial blood to the reperfusion injury. 
3. To investigate the impact of early rearterialization on the reperfusion injury after liver 
transplantation. 
4. To investigate the effect of the new preservation solution , Celsior, on the reperfusion 
injury after liver transplantation . 
Large White X-Landrace pigs were subjected to orthotopic liver transplantation. The donor 
liver was stored in Eurocollins solution for 3 hours. The animals were randomly allocated to 
either rearterial ization 60 minutes after portal reperfusion , rearterialization 20 minutes after 
portal reperfusion , simultaneously portal and arterial reperfusion , and rearterialization 20 
minutes before portal venous reperfusion . 
In another experiment, the donor livers were stored in either Eurocollins solution , University 
of Wisconsin Solution, or Celsior. 
II 
Blood samples were taken at various intervals and subjected to the following biochemical 
investigations. Malondialdehyde and vitamin A were used as markers of reperfusion injury. 
Hyaluronic acid levels were used as markers of endothelial cell function . Serum AST was 
used as a marker of hepatocellular injury. 
In summary, these studies showed that there was a significant reperfusion injury after portal 
venous reperfusion with no additional injury after rearterialization . Early rearterialization also 
resulted in a lesser reperfusion injury. There was also less hepatocellular injury with early 
rearterialization . Histological evidence of injury was also less in the livers which were 
rearterialized early. In addition , the livers preserved in Celsior had evidence of a lesser 
reperfusion injury. Thus in conclusion, in liver transplantation early rearterialization might 
result in better early graft function . 
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Arterial levels of Malondialdehyde (µmol/1) from 25 minutes before completion 
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(Group 1 = initial portal reperfusion ; Group 2 = initial arterial reperfusion) 
Arterial levels of Vitamin A, (mg/I) from 25 minutes before till 60 minutes after 
completion of revascularization . 
(Group 1 = initial portal reperfusion ; Group 2 = initial arterial reperfusion) 
Peripheral venous levels of AST (IU) post transplantation . 
(Group 1 = initial portal reperfusion ; Group 2 = initial arterial reperfusion) 
Hepatic venous levels of Hyaluronic Acid (µg/1) after transplantation . 
(Group 1 = initial portal reperfusion; Group 2 = initial arterial reperfusion) 
Arterial levels of serum AST at base, 1, 2 and 4 hours post transplantation in 
international units. 
Arterial Malondialdehyde concentrations during and after liver transplantation 
in µmol/1. 
Arterial Vitamin A levels from base till 60 minutes after liver transplantation in 
mg/I. 
Serum Hyaluronic Acid levels at base up to 60 minutes post transplantation in 
µg/1. 
Mean hepatocyte vacuolization after liver transplantation in the four groups in a 
semi-quantitative score from O to 5. 
Mean single cell necrosis after liver transplantation in the four groups in after 









Mean group cell necrosis in the four groups after liver transplantation in a 
semi-quantitave score. 
Mean neutrophil infiltration after liver transplantation in the four groups in a 
semi-quantitative score. 
Mean Serum AST levels after liver transplantation in the 3 groups in 
international units. 
Arterial levels of Malondialdehyde at various times during after liver 
transplantation in µmol/1. 
Arterial levels of Vitamin A at various times during and after liver 
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Hepatocyte vacuolization . Original magnification 1 OOX. 
Hepatocyte vacuolization . Original magnification 400X. 
Single cell necrosis of hepatocytes. Original magnification 200X. 
Single cell necrosis of hepatocytes. Original magnification 400X. 
Group cell necrosis of hepatocytes. Original magnification 200X. 
Group cell necrosis of hepatocytes. Original magnification 400X. 
Neutrophil infiltration in the transplanted liver. Original magnification 200X. 
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Preservation injury (Pl): 
The injury sustained to parenchymal and reticulo-endothelial cells which occurs from the 
time of bloodflow arrest in the donor to the time of reperfusion in the recipient. 
Reperfusion injury (RI): 
The injury wh ich occurs at the time of revascularization of the graft. 
Preservation-reperfusion injury (PRI): 
The combination of preservation injury and reperfusion injury. 
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CHAPTER 1 
Liver Transplantation - General Review 
Introduction 
In the twenty years after the first reported human liver transplantation by Thomas Starzl 1 in 
1963, liver transplants were performed in only 10 centres worldwide, the total number being 
only 500. In 1993, thirty years after the first liver transplant over 3500 liver transplants were 
performed in a total of 88 centers 2 3. It has now become established as the only definitive 
cure for acute and chronic end-stage liver disease. All other forms of therapy can be 
described as either disease prevention, prophylaxis or a palliation 4 5 . 
The increasing numbers of liver transplants being performed have forced both physicians and 
surgeons to confront the complex and unique clinical problems of the liver transplanted 
patients 2. The results of liver transplantation were initially poor. The reasons for this 
included surgical and technical problems, graft rejection , poor organ function , overwhelming 
infection and poor organ availability 6 7. Currently, more than 5000 liver transplants are 
performed annually 8 9 10 11 , with an overall 5 year success rate of approximately 75-80% 12 , 
and generally a good quality of life 13. 
History 
T E Starzl performed the first human liver transplant in 1963. Initial attempts of experimental 
liver transplantation were made in dogs and involved the insertion of a second liver as an 
auxiliary or heterotopic graft 14 15 . It was thought that the remaining function of the fail ing liver 
would provide some reserve in the event of poor performance of the transplanted liver. 
However, results obtained with auxiliary liver transplantation have been consistently inferior to 
those obtained with orthotopic liver transplantation 16. Much of the early experimental work 
with orthotopic liver transplantation was performed by Cannon 17, and subsequently by Starzl 
and Caine 18 19_ There was initially a high fai lure rate due to formidable complexities in 
surgical technique, as well as poor quality of the implanted organ. 
The initial results with clinical liver transplantation in Denver, Boston and Paris were poor. A 
moratorium was declared to allow further research 20 21 22 . Only after the NIH Health 
Consensus Development Conference in 1983 did liver transplantation progress from an 
experimental procedure to an accepted mode of therapy for patients with end-stage liver 
failure. In the 1980's the one-year survival following liver transplantation improved from about 
30% to over 70%. 
One of the major reasons for the improvement of these results was the introduction of the 
immuno-suppressant cyclosporin A. Other factors included improved histological monitoring 
for early signs of graft damage, refinements in the surgical technique, improved anaesthesia, 
better post-operative monitoring and the introduction of a close working transplantation team . 
1 
Current State 
Indications for liver transplantation 
Indications for liver transplantation in adults are listed in Table 1.1. 
IRREVERSIBLE ADVANCED CHRONIC LIVER DISEASE 
Predominantly Cholestatic disorders 
Primary biliary cirrhosis 
Primary sclerosing cholangitis 
Chronic drug-induced cholestasis and biliary cirrhosis 
Predominantly hepatocellular disease 
Chronic virus-induced liver disease 
Hepatitis B 
Hepatitis non-A. non-B 
Hepatitis C 
Hepatitis D 
Chronic drug-induced liver disease 
Alcoholic liver disease 
Idiopathic autoimmune chronic active hepatitis and cirrhosis 
Wilson's disease 
Congenital hepatic fibrosis 
Predominantly vascular disease 
Budd-Chiari syndrome 
Veno-occlusive disease 
II FULMINANT HEPATIC FAILURE 
Viral Hepatitis 
A,B, D, non-A, non-B, Epstein-Barr virus (EBV), others 





Anti Tuberculosis Therapy 
Quinidine 
Other agents 
Wilson 's Disease 
Ill HEPATIC MALIGNANCIES THAT ARE NOT RESECTABLE BUT ARE CONFINED TO THE LIVER 
Hepatocellular carcinoma 
Cholangiocarcinoma 
Rare non-hepatocellular or bile duct tumors that arise within the hepatic parenchyma 
Isolated hepatic metastatic disease 
Carcinoid 
Others 
IV INHERITED METABOLIC DISORDERS 
Hemophilia A 
Type II hypercholesterolemia 
Primary hyperoxaluria type 1 
Table 1.1 Indications for liver transplantation in adults 
The list of indications continues to expand , so that liver transplantation should now be 
considered in nearly all patients with advanced chronic liver disease and fulminant hepatic 
failure. Liver diseases for which liver transplantation has been performed can be divided 
broadly in 4 groups: I) Advanced, irreversible chronic liver failure, II) Fulminant hepatic failure, 
Ill) Hepatic malignancies and IV) Inherited metabolic disorders. 
2 
Transplantation for inherited disorders, such as type II hypercholesterolemia, in which the 
metabolic defect resides in the hepatocyte are rarely applicable in adults, but is becoming 
increasingly important in the treatment of children. In young patients with primary 
hyperoxaluria type I, successful combined transplantations of the liver and kidney have been 
performed. The liver graft provides the missing enzyme (hepatic peroxisomal 
alanine:glyoxalate aminotransferase) and the kidney transplant corrects the irreversible 
kidney damage from oxalate urolithiasis and nephrocalcinosis. Similarly, transplantation has 
been used successfully for the treatment of hemophilia A 
One of the major problems in the management of a patient with liver disease is determining 
the optimal timing of the liver transplant procedure. Clinical and biochemical indications for 
liver transplantation are listed in Table 1.2 
I Acute liver failure 
Serum bilirubin >10-20 mg/dl and increasing 
Prothrombin time >10 seconds above normal and increasing 
Progressive hepatic encephalopathy (coma) 
II Chronic Liver Disease 
A Cholestatic liver disease 




B Hepatocellular liver disease 
Serum albumin < 2.5 g/dl 
Hepatic encephalopathy 
Prothrombin time > 5 seconds above control values and increasing 
C Factors common to both types of liver disease 
Table 1.2 
Portal hypertension with bleeding from esophagal varices 
Intractable ascites 
Recurrent spontaneous bacterial peritonitis 
Hepatorenal syndrome 
Recurrent episodes of biliary sepsis 
Development of hepatocellular carcinoma 
Clinical and biochemical indications for liver transplantation 
The symptomatology of end stage liver disease and the indications for surgery vary 
depending on the underlying hepatic disease. The most common clinical indications are 
intractable ascites, severe encephalopathy, variceal hemorrhage, deteriorating nutritional 
state or diminishing quality of life. 
Cholestatic liver disease patients may be transplanted for intractable pruritis, metabolic liver 
disease and recurrent or uncontrollable cholangitis. Several inborn errors of metabolism may 
be cured if the transplanted liver corrects the underlying metabolic defect. 
Complications of severe hepatic dysfunction, like new-onset ascites, variceal hemorrhage, 
hepato-renal syndrome, recurrent spontaneous bacterial peritonitis, spontaneous 
3 
encephalopathy and sustained severe jaundice are late manifestations of liver disease and 
represent an urgent consideration for liver transplantation 11 23. 
I ABSOLUTE CONTRAINDICATIONS 
A Active sepsis outside the hepatobiliary tree 
B Malignancy outside the liver 
C Advanced cardiopulmonary disease (except when heart/liver transplant is an option) 
D AIDS 
II RELATIVE CONTRAINDICATIONS 
A Advanced chronic renal failure (except when liver/kidney transplant is an option) 
B Age greater than 60 years 
C Portal vein thrombosis 
D Cholangiocarcinoma 
E Hypoxemia with intrapulmonary right-to-left shunt 
F HB,Ag and HB.,Ag positivity 
G Prior portosystemic shunt surgery 
H Prior complex hepatobiliary surgery 
I HIV positivity without clinical AIDS 
J Chronic alcoholism 
Table 1.3 Contraindications to liver transplantation 
Contraindications to liver transplantation are listed in Table 1.3. At present, the only absolute 
contraindications to liver transplantation are AIDS, extrahepatic malignancy, septicaemia and 
severe underlying cardiopulmonary or systemic disease 24 25 . Relative exclusions are prior 
extensive abdominal surgery, portal vein thrombosis, multicentric hepatoma or hepatoma 




The technique of liver transplantation has remained remarkably similar to the original 
description of orthotopic liver transplantation by Thomas Starzl in 1963. The complete 
transplant procedure is composed of four main stages 26: 
1. Donor hepatectomy 
2. Recipient hepatectomy 
3. Implantation of the graft 
4. Hemostasis and bile tract reconstruction 
Donor hepatectomy 
There are two basic techn iques of liver harvesting as part of multiple organ retrieval known as 
the "standard" or traditional technique and the "rapid" technique 27 . Both techniques are 
usually performed through a complete, midline sternum-splitting and abdominal incision. 
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After completion of the preliminary dissection, cannulae are inserted into the distal abdominal 
aorta and portal vein , via either splenic vein , inferior mesenteric vein or superior mesenteric 
vein , for the infusion of preservation solution. The liver can be pre-cooled by the infusion of 
cold Ringer's lactate solution through the splenic vein cannula prior to aortic cross-clamping, 
or the aorta can be cross-clamped without prior pre-cooling. 
Cold preservation solution (University of Wisconsin Solution) is then rapidly infused through 
the aortic and portal cannulae, while the liver is decompressed by dividing the suprahepatic 
inferior vena cava in the chest. After cooling , the origin of the hepatic arterial supply is 
detached from the aorta, the portal vein divided and the suprarenal infrahepatic vena cava is 
transected with part of the right adrenal gland to allow easy identification and ligation of the 
right adrenal vein at its entry into the retrohepatic inferior vena cava. 
The "standard" technique of liver procurement often requires two or even more hours of 
preliminary and meticulous dissection of the hepatic hilum. This prolonged manipulation of the 
liver can inadvertently produce a warm ischemic injury to the liver, and furthermore, such a 
lengthy procedure may not be tolerated by an unstable donor. In the "rapid" technique there is 
no preliminary dissection except for the encirclement of the proximal aorta and cannulation of 
the inferior mesenteric vein and distal aorta. Once the cardiac and renal teams are prepared, 
the aorta is cross-clamped and rapid infusion of ice cold preservation solution through both 
cannulae is begun. The heart is usually removed at this stage and the liver allowed to 
completely flush and cool. Hilar dissection is then safely completed in a bloodless field . The 
liver can often be removed within 30 - 60 minutes. This technique has increased the 
practicality of harvesting under various adverse circumstances. 
Recipient Hepatectomy 
Adequate exposure is usually achieved by a bilateral subcostal incision, with an upper T 
extension and excision of the xiphoid process. 
Previous right upper quadrant abdominal operations can render the removal of the recipient 
liver very demanding and tedious. The recipient hepatectomy usually represents the most 
difficult stage of the entire liver transplant procedure. It may be impossible to dissect the 
structures of the hepatic hilum individually because of prior surgery or because of the massive 
formation of varices. 
Veno-venous bypass 
The most critical period of the recipient operation is the anhepatic phase when the native liver 
has been removed and the inferior vena cava and portal veins have been occluded . This 
obligatory clamping of the splanchnic and infrahepatic systemic venous systems results in a 
massive sequestration of blood volume in the mesenteric venous circulation and in the 
systemic venous circulation of the lower body. Sequelae include severe oedema of the whole 
gastrointestinal tract, renal venous hypertension and an increase in bleeding from the thin-
walled venous collaterals. Other complications include volume overload , hemodynamic 
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instability, cardiac arrythmias and arrest on reperfusion , due to the accumulation of potassium 
and other toxic substances in the stagnant venous blood. 
These problems were overcome by the introduction of the pump-driven veno-venous bypass 
system (between the left external iliac and the left axillary vein) , without systemic 
heparinization, during the anhepatic phase of the adult recipient operation. This resulted in a 
significant reduction in morbidity and mortality 28. It also made liver transplantation an option 
in patients, previously assessed as too unstable to qualify for the procedure. Because of the 
possibility of a longer anhepatic phase, more operative options and numerous modifications in 
the technique of recipient hepatectomy were developed. Once the portal triad has been 
encircled, its constituent structures can be individually freed with relatively safety. Early 
placement of the veno-venous bypass greatly facilitates the mobilization of the liver from the 
hepatic fossa and the dissection of the vena cava. Appropriate vena caval cuffs and sufficient 
portal vein length must be developed before the graft is brought into the field for anastomosis. 
Graft implantation 
After adequate haemostasis of the liver bed has been assured, the supra- and infrahepatic 
vascular cuffs are prepared. It is much easier to deal with small leaks at this stage, rather 
than at the moment of revascularization . 
After the donor liver is positioned in the recipient hepatic bed, the suprahepatic vena caval 
anastomosis is performed with polypropylene sutures. Thereafter the infrahepatic caval 
anastomosis is performed. Prior to completion of the anterior side of the suture line, the liver 
is flushed with a minimum of 250 ml of a "flush out" solution to wash out the high-potassium 
containing preservation solution and the air entrapped inside the liver. 
The portal veno-venous bypass cannula is then removed and the portal vein is trimmed to the 
appropriate length. The portal venous anastomosis is then performed, and the portal, 
infrahepatic and suprahepatic vascular clamps removed, and the liver revascularized . After 
controlling major leaks with interrupted sutures, the veno-venous bypass is interrupted and 
the remaining cannulae removed. An "expansion" or "growth factor" is used to prevent suture 
line stenosis, especially for the portal vein and hepatic artery 29. The donor hepatic artery is 
anastomosed to the recipient hepatic artery. Reconstruction of the bile duct is achieved by 
either a choledocho-choledochostomy or a choledocho-jejunostomy with a Roux-Y loop. 
Modifications of the surgical technique 
(a) Split and reduced-size liver transplantations 
Reduced size liver transplantations were developed in response to the shortage of donor graft 
organs for paediatric patients. Usually the left lateral segments, the left lobe or the right lobe 
are transplanted. Patient and graft survival are similar to intact liver transplantation 30• 
Success with reduced size liver transplantation led to the development of split-liver technique, 
in which one liver is split into two functioning units and used for two recipients 31 . This 
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Success with reduced size liver transplantation led to the development of split-liver technique, 
in which one liver is split into two functioning units and used for two recipients 
31
. This 
technique is far more challenging, since extensive reconstruction of the segmental vessels 
and biliary system are required . The initial poor results were due primarily to the selection of 
poor-risk recipients 3
2
. It is now performed with good results in selected, experienced centers 
33 34 
{b) Living related liver transplantation 
Recently, living related liver transplantation has been proposed as a possible solution to the 
liver donor shortage 
35 36 37
. Initially introduced for paediatric patients, this technique is now 
also used in adults. In some countries like Japan, where brain death laws were not 
established, most orthotopic liver transplants were from living related donors. Unfortunately, 
one third of potential living related donors are unsuitable either because of liver problems or 
due to underlying medical conditions. The risk to the donor is low. The one year survival rates 
for the recipient are excellent and approach 100% in elective cases 
35
, while results from 
procedures performed under emergency circumstances remain poor (50-60% one year 
survival) . 
(c) Auxiliary liver transplantation 
Heterotopic (auxiliary) liver transplantation has been proposed for fulminant hepatic failure, 
with the ultimate goal to bridge the patient to allow recovery of the native liver 
38
. It has also 
been performed for end-stage chronic liver disease 
39
. 
A recent modification involves partial resection of the native recipient liver and implantation of 
part of the donor liver in the orthotopic position, ie auxiliary partial orthotopic liver 
transplantation (APOL T). 
The main advantage of auxiliary liver transplantation is that recovery of the native liver 
function eliminates the need for chronic immunosuppression. The disadvantages include a 
higher number of vascular complications. 
7 
lmmunosuppression 
Most liver transplant centers currently use a triple-drug regimen (prednisone, either 
cyclosporine or tacrolimus, and azathioprine). Some centers use induction 
immunosuppression with antilymphocyte globulins, such as OKT3 (Muromonab-CD3, 
Orthodone, Ortho Pharmaceuticals, Raritan, NJ) or Atgam (antilymphocyte globulin(equine), 
Upjohn Co, Kalamazoo, Mich). The reason for antilymphocyte induction is to avoid the 
potential nephrotoxicity of either cyclosporine or tacrolimus 2. 
Results 
Up to 1980 results from human liver transplantations were poor. 1-year survival was 
approximately 30% and survival beyond 30 months approximately 20%. Improvements in 
surgical techniques and advances in immunosuppression have been the main reasons for 
improved patient outcome. At present the average 1- and 3- year's survival rates in the United 
States of America are 77% and 68%, respectively, and 73% and 65% in Europe 2. Deaths 
within the first 6 months are caused by primary non-function of the allograft, hepatic artery 
thrombosis, infection, multi-organ failure or allograft rejection . Late death is commonly caused 
by atherosclerotic disease or malignancy. 
Future 
(a) Problems with donor pool 
The major concern for the future is the shortage of donor organ availability. Between 1988 
and 1995 the waiting list for liver transplantation increased by almost a 1000% 40 41 . This has 
fuelled major controversies like the limitation of the number of liver transplantation centres, 
selection criteria for potential transplant recipients and changes in the present allocation 
system for donor livers 42 . 
Improved road safety and initial medical care of severely injured patients have both resulted 
in a reduced number of potential organ donors 43• Extending the donor pool using non-heart-
beating donors seems unfeasible, until new strategies to attenuate warm ischaemic liver 
injury still have been developed 44 45. 
A key issue is whether the available livers should be given to the sickest patients, despite the 
lower survival rate or should be used for patients with a better chance. 
(b) Xenografting 
Xena-transplantation of the liver in both Pittsburgh and Los Angeles has generated 
considerable interest, although it has to be stressed that so far, xenograft liver transplantation 
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has not resulted in long-term survival 46 47 48 49 . The perceived immuno-privileged status of 
the liver might well open the way for xenografting in the future, especially since the xenograft-
rejection mechanism is now better understood and can be therapeutically modulated. 
Strategies to break through the immunological barrier in xeno-transplantation include 
modulation of xeno-reactive antibodies by inhibiting their binding by either using soluble 
ligands or inhibiting complement activation. Donor pigs transgenic for human decay 
accelerating factor showed a significant attenuated complement activation 50. Xeno 
transplantation might well be the only answer to the donor shortage in the long-term. 
(c) Hepatocyte transplantation 
Transplantation of isolated hepatocytes was initiated in 1970 51 52. Hepatic failure is unlikely 
to respond to this therapy since it requires large amounts of readily available hepatocytes. 
However success has been reported with this technique in clinical studies during the bridging 
period in patients with fulminant hepatic failure 53. For metabolic diseases, however, this 
technique is promising. Gene therapy can be applied either in-situ by directly coding in the 
defective liver or portal vein , or ex-situ by gene manipulation of hepatocytes. Recently, 
several successful experimental studies have been reported using either isolated hepatocytes 
or hepatocytes encapsulated in semi-permeable hollow fibers 54 55 . 
(d) Extracorporeal whole organ perfusion and liver dialysis 
The use of extracorporeal liver perfusion to provide support in patients with liver failure was 
first studied experimentally by Otto et al in 1958 56. Human organs were used for 
extracorporeal liver perfusion by Fox et al 57. There were also reports describing attempts to 
use an extracorporeal pig liver perfusion as a bridge to liver transplantation 58. Early pig liver 
dysfunction seems to be the limiting factor. Future modulations of this technique may use 
transgenic porcine liver perfusion to minimize the immunological damage to the liver grafts. 
The concept of liver dialysis has been introduced with the bioartificial liver. In this technique 
hepatocytes are attached to micro-carriers and placed in a bioreactor, through which the 
patients blood is circulated. Once a semi-permeable membrane is established , animal 
hepatocytes can be used without rejection 59. Several experimental successful studies have 
been recently reported 60 , and a phase I clinical trial of a Bioartificial liver (BAL) system has 
been recently completed , with promising results 61 . Although this technique promises to keep 
patients with acute hepatic failure alive, it is as unlikely to offer a definitive solution for chronic 
hepatic failure as renal dialysis offers a solution for chronic renal failure. 
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CHAPTER 2 
Preservation - Reperfusion Injury - Review 
Introduction 
(a) Preservation Injury 
In transplantation, there is a significant delay between the harvesting of the donor organ and 
the subsequent implantation of the organ into the recipient. The donor organ often has to be 
transported over significant distances to arrive at the most compatible recipient. 
During this time, the donor organ is in a severely unphysiological state and is not being 
perfused. To decrease the metabolism during this phase, the donor organs are stored on ice 
62
. Prior to storage the livers are perfused with specially designed preservation solutions to 
minimize the damage. The liver is eventually removed from its cold environment, located in 
the recipient's abdomen, and anastomosed. During this phase, it is impossible to maintain 
the low temperature of the donor-organ and rewarming takes place. Rewarming invariably 
leads to increased metabolism, with depletion of the energy stores. It takes a substantial time 
before the liver is reanastomosed and ready for reperfusion. The injury is thus aggravated by 
a compulsory anaerobic metabolism with accumulation of toxic products. Functional and 
structural damage during ischaemia is well documented 63 64 65 66 67 68 69 70 71 72 73 74 75. This 
injury is commonly known as the preservation injury. 
(b) Reperfusion Injury 
It is now well established that reoxygenation of hypoxic tissue can lead to a sequence of 
events, which is similar to the consequences of prolonged hypoxia, and includes cell injury 
and necrosis 76. In fact the injury elicited by reperfusion can be more severe than the injury 
induced by the ischaemia per se 77. Although the exact mechanism is still unknown and is 
most likely to be multifactorial , the tissue injury at reperfusion seems to be mediated by 
reactive metabolites of molecular oxygen 78 79. lschaemic tissues must be exposed to 
molecular oxygen on reperfusion to manifest tissue injury 80. Reperfusion therefore seems to 
initiate a series of cytotoxic events that are associated with the return of oxygenated blood . 
There has been an increasing interest in the preservation-reperfusion injury of the 
transplanted liver, in order to gain further insight into the complicated mechanisms of 
transplantation, as well as improving the results of liver transplantation. Primary non-function 
of the transplanted liver still occurs at an unacceptably high rate (up to 20%) and continues to 
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be a major cause of death after transplantation 81 82 83. There is also clinical evidence 
indicating that a severe reperfusion injury is associated with an increased incidence of liver 
graft rejection 84. 
HISTORY 
(a) Hypothermia 
It was recognised early on that the normothermic liver is extremely sensitive to hypoxia 15. 
Complete anoxia of only 30 minutes renders the normothermic liver totally unsuitable for 
transplantation. In 1960, hypothermia was induced by means of whole-body cooling of the 
donor to 30°C, after which the excised liver was perfused with cold (4°C) Ringers' lactate 
solution. In this way, the liver could be cooled down to approximately 15°C. These livers were 
able to sustain life in the recipient dogs, if transplanted within 2 hours 19. Longer preservation 
times led to a higher rate of acute failure, due to outflow block of the livers, haemorrhagic 
diathesis and acute liver failure. 
New developments in organ preservation were quickly interchanged between livers and 
kidneys. Cold preservation solution infusion into the liver rapidly became standard practice for 
renal cooling 85. 
Attempts to cool livers down to -60°C to preserve the liver for longer periods were less 
successful 86 87 . 
(b) Perfusion Techniques 
It was also recognised early on that perfusion of the grafts could significantly reduce the time 
periods of cooling as well as rewarming 88 . Techniques were developed to perfuse the liver in-
situ with an extracorporeal heart-lung machine 89 or perfusion of the liver in-situ selectively 90. 
The first 15 human liver transplants were all revascularized within 3Y:z hours after the donor 
death 91 92. In 1967, prolonged storage (24 hours or more) of kidney as well as liver grafts was 
demonstrated using the technique of extra corporal hypothermia pulsatile perfusion 93 94. The 
results with liver preservation were very variable, most likely due to variations in type and 
length of the preservation, composition of the perfusion-solution , the applied technique 
(intermittent, continuous, pulsatile , non-pulsatile) and of course, the individual response of the 
liver graft to such injury 42. 
(c)Preservation Solutions 
In 1969 95 , Collins described successful canine kidney preservation with a similar technique of 
initial perfusion, followed by a 30-hour period of ice-storage. This was adopted for liver 
transplantation by the Denver/Pittsburgh group 96. The method of initial perfusion followed by 
simple hypothermic storage was gradually adopted as the best method. 
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In 1971 , successful experimental liver transplants were reported after simple storage of the 
graft for 6-8 hours, using balanced salt solutions, to which dextrose was added 97 98 . Several 
new preservation solutions were developed , but since the storage time hardly exceeded a 12 
hour period, no clear differences in results could be demonstrated 96. However, in longer 
preservation times (18 hour storage) , there was a clear advantage of Collins' solution over 
Ringer's lactate, as reported by Benichou et al 96 . 
The same authors also reported on their clinical experience with human liver preservation, 
using modified Collins' solution. Subsequently, the role of the modified Collins' solution, or its 
more modem derivative Euro-Collins, was established, and most centres used it until the 
introduction of the University of Wisconsin solution in 1988 99. 
Preservation Injury 
Pre-preservation Component 
The pre-preservation period is defined as the time between injury to the donor and the 
perfusion of the graft with ice-cold preservation solution. There are numerous donor factors, 
which can play a major role in the ultimate success of the liver transplantation. 
(a) Demographics 
Several donor factors have been identified as having a negative effect on the ultimate 
outcome. The extremes of age have a negative impact on the results of liver transplantation. 
A prolonged hospital stay, elevated bilirubin and death from a traumatic head injury are also 
correlated with poor outcome 100. A prolonged donor stay in the intensive care unit (more than 
5 days) should be carefully evaluated, especially if there are other relative risk factors 
present. 
The liver might also be injured subclinically by substance-abuse. Drugs as well as alcohol 
might have been consumed by the donor chronically or in high amounts just before the event 
of death. Any illness or injury leading to brain death, such as hypotensive episodes, hypoxia 
or anaemia, might also result in an injury to the liver. 
(b) Metabolic Changes in the Donor 
Brain death is associated with profound endocrine alterations, which can lead to 
hemodynamic instability and other complex metabolic disturbances 101 102 103 104. Eighty per 
cent of donors develop diabetes insipidus 105 due to decreased secretion of vasopressin from 
the posterior pituitary, none of the anterior pituitary hormones show a decline in concentration 
103 106
. An example of endocrine pathology induced in this phase is the euthyroid sick sinus 
syndrome 101107. 
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The nutritional state of the transplanted liver is also a crucial factor. Glycogen stored in the 
liver is a substrate for anaerobic glycogenolysis as well as glycolysis, and might protect 
against ischaemia 108. Therefore, depleted glycogen stores are likely to predispose the 
transplanted liver to an increased preservation injury 109 11 0 11 1 112 . Livers from fed rats are 
more resistant to ischemic damage than livers from fasted rats. Experimental studies show 
that this beneficial effect can be achieved directly, via a higher level of adenosine 
triphosphate 113, or indirectly, via lowering the intracellular pH as a result of a higher level of 
lactic acid 114 115 116. These studies have been confirmed in humans 117 118 . Preservation-
reperfusion injury has been diminished in experimental studies in rats, rabbits and pigs, by 
nutritionally replenishing the liver before transplantation 112 119. Protection against warm 
ischaemia has also been shown with nutritional replenishment 120. 
Fatty infiltration, wh ich can be found in approximately 20% of donor livers, has a significant 
impact on the outcome of the transplant 82 121 . The aetiology and natural course of hepatic 
steatosis has been well described 122 123. Although certain histological changes have been 
identified with prolonged preservation times, no objective data for not transplanting livers with 
hepatic steatosis are available. Several anecdotal reports have described primary non-
function of livers with fatty infiltration 124 125, and it has been suggested 126 127 128 that less than 
60% fatty cells is acceptable. Hepatic steatosis related to total parenteral nutrition or alcoholic 
hepatitis 129 130 represents a higher risk for the recipient. 
Not all steatosis is related to pre-existing disorders. There is a correlation between 
physiological stress and steatosis 131 132 . This might indicate that the cause of steatosis is 
related to events occurring just before and during the phase leading to brain death in the 
donor. 
The exact mechanism of hepatocellular damage by steatosis is unknown. Cooling of the liver 
might solidify triglyceride droplets resulting in hepatocyte rupture. Extracellular coalescence of 
fat globules might further disturb the liver architecture and microcirculation, in itiating an 
inflammatory response and resulting in lipid peroxidation 122 124. Development of strategies to 
reduce hepatic steatosis in the liver graft could expand the donor pool as well as lead to an 
improved initial graft function . 
Another potential source of injury to the liver graft is the exposure of the organ to circulatory 
toxins. These can be either chemical or organic. Endotoxemia is a common event in the 
terminal patient and can injure the liver significantly 133 134 135 . 
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Cold Preservation Injury 
The cold preservation injury is the injury which occurs from the time of perfusion with cold 
preservation solution until the moment the liver is removed from the preservation solution . 
Hypothermia slows the metabolism, reduces tissue energy requirements and waste 
production. Cold anoxia, however, induces numerous destructive processes, including energy 
depletion, pH changes due to anaerobic glycolyses, and electrolyte and water movement 
across the cell membrane secondary to inhibition of the Na/K ATPase-dependent pump.66136 
(a)Sinusoidal Lining Cell Injury 
During the cold preservation period the sinusoidal lining cells are the first cells to be affected. 
Hypothermia usually results in injury to all cells, irrespective of their origin 137. There is 
however substantial evidence to indicate that in the liver the injury to the sinusoidal cells is of 
more importance than the injury to the parenchymal cells 138 139 140. Sinusoidal lining cell 
injury was first demonstrated in 1984 by means of electron microscopy 141 . The typical 
sequence of progressive sinusoidal cell injury, as demonstrated by electron microscopy, is 
swelling, fenestration and eventual detachment of the substratum 142 143 144. 
(b)Anaerobic Metabolism 
In aerobic cells, the cell integrity is maintained by energy supplied by the mitochondrial 
cytochrome system using reduction of oxygen to water. ATP is generated in this process, 
and stored in the cell for use at a later stage. This oxidative phosphorylation ceases at the 
arrest of oxygen supply. During cold preservation ATP-stores are rapidly exhausted and since 
ATP is crucial to nearly all energy depending functions of the cell , the ATP shortage quickly 
leads to impairment of cell functions, progressive cell injury and eventually to cell death 65 . 
Although the exact pathway from ATP shortage to ultimate cell death is unknown, several 
morphological changes are well described . These include loss of microvilli and "blebbing". 
"Blebbing" of the cell surface was first described in 1987 145. Rupture of a terminal cell 
surface bleb seems to be associated with the progression from reversible to irreversible injury, 
and is thought to be the result of disruption of the cytoskeleton 145. The F-actin structure, 
which maintains the cytoskeleton of the cell becomes deranged due to the loss of ATP as an 
energy substrate. G-actin forms by means of depolymerization and is most likely the initial 
event in endothelial cell injury 146 147. 
(c)The Cytoskeleton 
The whole microfilamental and microtubule network, which forms the base of the 
cytoskeleton, is permanently in an energy requiring , dynamic state of continuous formation 
and disassembly. It is thus likely to be affected instantly if ATP shortages occur 65. The rapid 
loss of energy sources during cooling is therefore likely to affect the normal cytoskeleton. 
Rounding of endothelial cells has been documented in short cold-stored livers, whereas 
prolonged periods of cold ischaemia can lead to a total endothelial denudation 143. 
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Due to absence of the collagenous basement membrane between parenchymal and 
endothelial layers in the liver 148 , retraction of cytoplasmic processes can expose hepatocyte 
microvilli direct to the sinusoidal lumen 149 150. 
Several groups have shown that the majority of sinusoidal lining cells are still alive at the end 
of the cold storage period 151 152. Although delayed death can occur after reoxygenation , 93% 
of the sinusoidal cells remained alive after transplantation and were even able to retract to the 
substratum 11 9 . Cold preservation injury with subsequent cell death does not occur secondary 
to a metabolic derangement, but occurs when the endothelial cells undergo cytoskeleton 
alteration and lose their substratum connections. Endothelial cell death, therefore, per se is 
not a prerequisite for cold preservation injury. Prolonged periods of cold storage invariably 
lead to endothel ial cell death . However, reperfusion after short periods of cold storage, will 
supply ATP for the energy dependent cytoskeletal reorganizations with endothelial cell 
spreading, migration and regeneration . 
(d)Biochemical Evidence for the Role of Sinusoidal Lin ing Cells 
Besides the morpholog ical changes described above, there is also biochemical evidence for 
the role of the sinusoidal lining cells in cold preservation injury. The iso-enzyme creatine 
kinase BB is solely released by Kupffer cells and hepatic endothelial cells. The length of cold 
preservation has been shown to correlate with the severity of the endothelial cell damage and 
creatine kinase BB levels 153 154. Furthermore, hepatic endothelial cells are the only 
endothelial cells which can metabolize hyaluronic acid (Ha) and Ha levels have been used as 
a sensitive ind ication of hepatic endothelial cell function 155. An inverse correlation has been 
shown between Ha uptake and the duration of the cold preservation and the severity of 
endothelial cell injury 156 157. Ha levels have also been used as a marker for hepatic 
endothelial cell function after transplantation 158 159 160. 
Rewarming injury 
Rewarming injury occurs during the period when the allograft is removed from the 
preservation solution and implanted into the recipient prior to reperfusion . Th is is referred to 
as the second warm ischaemic injury. In liver transplantation , this period lasts approximately 
from 30 to 90 minutes and has been shown to be an important cause of hepatocellular injury 
66 117 161 162 163
. With prolonged rewarming there is an exponential increase in graft injury. In an 
experimental study, all liver transplants with a warm ischaemia time of longer than 90 minutes 
resulted in death44 . Specific morphological changes occur in the liver during warm ischaemia, 
and include a decrease in the number of hepatocyte microvilli , cytoplasm vacuolization and 
partial plasma membrane rupture 164. This is followed by mitochondrial swelling and 
displacement of the endoplasmatic reticulum fragments and ribosomes. After 2 hours, 
denaturation and dislocation of cell macromolecules in the hepatocytes takes place 165. The 
development of surface "blebs" and loss of microvill i has been associated with the transition 
of reversible into irreversible ischemic damage 65 166 167 168. Breakdown of bleb-membranes is 
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thought to result in cell membrane damage and perforation, leading to an irreversible 
permeability of organic cations and anions. 
The exact nature of rewarming and warm ischaemia is not fully understood. It is likely that an 
increase in temperature will lead to an increase in anaerobic metabolism, and subsequent 
loss of energy substrates 169. It has been demonstrated experimentally that a glycogen-
repleted donor liver will have used approximately 70% of its glycogen stores after 1 hour of 
warm ischaemia 170. Several studies have indicated that enhanced ATP synthesis and prompt 
recovery of energy charge after revascularization are prerequisites for normalization of 
metabolic liver function 171 172 173. It has also been suggested that normalization of energy 
charge indirectly reflects the maintenance of mitochondrial integrity during ischaemia which is 
essential for graft viability 44 174• 
Reperfusion Injury 
Introduction 
In the classic reperfusion injury, the severity of the injury is directly related to the duration and 
severity of the cold ischaemia as well as the duration of the second warm ischaemic period. 
Thus, during reperfusion , the injury, which has germinated during the ischaemic hypothermia 
and the ischaemic rewarming phase is first expressed in full scale. The mediators responsible 
for the evolution of reperfusion injury can only be produced in sufficient quantity when 
reperfusion is achieved with oxygenated blood. The severity of the reperfusion injury has 
been demonstrated to be directly dependent on the severity and duration of the hypothermic 
period 112 139 175 176 177 178. Furthermore, there exists a certain point following prolonged (cold) 
ischaemia, after which the tissues are irreversibly damaged. Subsequent reperfusion is 












Figure 1. Diagram of the course of a typical reperfusion Injury: at a certain 
point reperfusion injury can not exceed the ischaemic injury any 
more. 
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The classical understanding of the reperfusion injury is that it is caused by reoxygenation of 
the ischaemic donor organ. The process is further complicated by a variety of allo-immune 
reactions between the donor organ and the recipient. 
The Role of Various Cell Types in Reperfusion Injury 
Hypothermia causes injury to all cell lines. However, several specific cells have been reported 
to be crucial for the initiation and progression of reperfusion injury. Unlike other solid organs, 
the parenchymal cells in the liver seem to play only a minor role in PRI. Otto and McKeown 141 
179
, were the first to realize the importance of the morphological changes of the sinusoidal 
lining cells during hypothermia, and since then this has been at the centre of reperfusion 
research . Other researchers have stressed the role of the Kupffer cells 177 180 181 182 183, 
leukocytes and platelets 176184 185 186. Although all these cell lines do play a role in the ultimate 
reperfusion injury, the most likely mechanism of preservation-reperfusion injury is a 
complicated multifactorial process, occurring in the hepato-sinusoidal complex. The various 
mechanisms do not follow the easy laws of cause-and-event, but a complicated interplay 
exists with potentiating of effects. 
(a)Sinusoidal lining cells 
The importance of the sinusoidal lining cells (SLC) in the pathogenesis of reperfusion injury 
has been apparent for many years 141 179. The major changes in these cells are initiated 
during the cold ischaemic period. A detailed description of the changes occurring in the SLC 
can be found on page 14. 
(b)Kupffer Cells 
Approximately 70% of all reticulo-endothelial cells reside in the liver. These liver 
macrophages are commonly known as Kupffer cells and represent approximately 30% of all 
sinusoidal lining cells 187 . At rest, Kupffer cells are flattened and spread out over the 
endothelial cells to form the inner sinusoidal lining 180 188. After cold preservation, these cells 
increase in volume, with increased vacuolization , increased granular formation inside the 
vacuoles and polarization of granules towards the luminal surface 177 178. Identical changes 
are noted in macrophage activation 180 188. These changes are followed by the release of 
lysosomal enzymes into the intra-vascular compartment. Evidence for a crucial role of the 
Kupffer cells in reperfusion injury was reported by Thurman et al. 189 190 191 , who found that the 
blockade of the Kupffer cells with either methylpalmitate or nisoldipine resulted in a significant 
increase in graft survival. They demonstrated activation of Kupffer cells on reperfusion in a 
low-flow reflow perfusion model. Although it is now well established that Kupffer cells do play 
a major role in the pathophysiology of preservation-reperfusion injury 177 180 192 , it remains 
unclear if this role is primary or secondary 180 181 182 188 189 190 191 . It has been noted in several 
studies that changes in the endothelial cells precede those in Kupffer cells. It has therefore 
been assumed that Kupffer cell changes are secondary to endothelial cell damage. Moreover, 
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Kupffer cell activation occurs usually only after a considerable time (approximately 30 
minutes) after reperfusion , which also precludes a primary role 177 193. 
Inhibition of the reactive oxygen intermediate production of Kupffer cells does not ameliorate 
the sinusoidal lining cell injury produced by preservation-reperfusion injury 194. Initially, nearly 
all stud ies concerning the role of the Kupffer cell in preservation-reperfusion-injury (PRI) of 
the liver were based on morphological signs of the Kupffer cell activation. It has to be 
stressed that at the time these changes occur, the sinusoidal endothelial cells (SEC) changes 
have already taken place a substantial time before. 
The majority of studies reporting improved graft survival after Kupffer cell blockade with 
various substances such as nisoldipine, pentoxifylline, adenosine and prostaglandin E, do not 
refer to several other known and possible unknown effects of these substances, which might 
well be a major factor in reducing the PRI. Nisoldipine, a dihydro-pyridine calcium channel 
blocker, has been shown to decrease Kupffer cell activation if added to the preservation 
solution 195. Kupffer cell activation might be the consequence of an increase in calcium during 
the preservation-reperfusion period. However, calcium is known not to be the major factor in 
hypoxic cell damage. 
Like all other macrophages, Kupffer cells synthesize and release a large variety of 
inflammatory mediators, such as reactive oxygen intermediates (ROI ), leucotrienes, 
cytokines, hydrolytic exzymes, chemotactic substances and tumour necrosis factor alfa 
(TNFa) 196 197 198 199 200 201. TNFa, amongst other functions, controls the systemic response to 
endotoxins and sepsis and also mediates pulmonary leucocyte infiltration after hepatic 
ischaemia and reperfus ion 202 203 . Endotoxin , or lipopolysaccharide (LPS), is able to strongly 
stimulate TN Fa production by Kupffer cells. A number of agents that suppress LPS stimulated 
TNFa formation by Kupffer cells, also improve graft survival after PRI in experimental models 
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. Nisoldipine, adenosine, pentoxifylline and prostaglandin E all belong to this category. 
Suppression of Kupffer cell release of TNFa and other proinflammatory cytokines is the 
possible working mechanism for the beneficial effect of graft recipient treatment with 
prostaglandin E in clin ical liver transplantation and pentoxifyllin in experimental models 81 204 
205 
Other mechanisms through which Kupffer cells might influence the severity of PRI , are 
secretion of leucocyte and macrophage chemotactic and stimulatory substances 196 206 and 
stimulation of pro-coagulant activity 207. TN Fa might further initiate expansion and synthesis of 
intercellular adhesion molecules (ICAM's) mediating an increase in leucocyte-sticking 208 209 
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All these effects result in a major disturbance of the hepatic microcirculation. Kupffer cells 
also influence hepatocyte function independent of the microcirculatory changes, via formation 
of glycoprotein , lymphokines and growth factors 188. Kupffer cell injury might therefore result in 
a decreased recovery of hepatic parenchymal cells after PRI. In addition, Kupffer cells have 
also been shown to play an important role in liver regeneration. 
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Mediators produced by Kupffer cells, and released into the systemic circulation , might 
contribute significantly to the development of multiple organ failure associated with primary 
nonfunction of the transplanted liver 201 . Several other Kupffer cell inhibitors, including 
gandolinium 139 206 211 212 and latex particles 192 , have been shown to improve the outcome 
after PRI , although the exact underlying mechanism has not yet been clarified . The 
complexity of reactions taking place in the hepatic microcirculation after ischaemia make it 
unlikely that a single factor is responsible for severity of PRI. 
( c) Leucocytes 
There are numerous studies about the role of leucocytes in the pathobiology of PRI 80. 
Leukocytes are thought to play a major role in PRI. This view is based largely on three lines of 
evidence: (a) Granulocytes accumulate in the tissues exposed to ischaemia and reperfusion , 
(b) Depletion of circulating neutrophils significantly reduces the microvascular and 
parenchymal cell dysfunction associated with PRI and (c) agents that prevent neutrophil 
activation of leucocyte-endothelial cell adhesion effectively decrease PRI induced tissue 
injury. 
Adhesion of leucocytes on reperfusion suggests that the sinusoidal lining has been altered. 
Since postischaemic tissues generate large quantities of leucotriene 84 (L TB4) , platelet 
activating factor (PAF), C5a and numerous other chemo-attractants, it is of little surprise that 
these tissues are infiltrated with neutrophils. Lymphocyte adherence to sinusoids occurs 
within 1 O minutes after reperfusion of cold preserved rat livers, and the degree of adherence 
is related to the duration and intensity of the cold ischaemia 66 176. Using intra-vital video 
microscopy, it is possible to quantify the leucocyte-endothelial cell adhesive interactions. 
After 45 minutes of cold ischaemia approximately 40% of circulating lymphocytes adhere to 
the sinusoids, while after 30 hours of cold storage, this number is increased to more than 80% 
213 214 21 5 
The leucocyte adherence is also dependent on the grade of inflow occlusion . In low-flow 
ischaemic models, the adherence is 4-10 fold increased, while in complete arterial occlusion 
models the adherence is increased 45 fold 80 216 . Several studies have shown a correlation 
between neutrophil adhesion in the hepatic sinusoids and primary graft function 215 217 in 
clinical liver transplantation , as well as a correlation between leucocyte adhesion and the 
extent of the preservation injury 154. 
( i )Leucocyte Trapping 
Although the leucocyte-endothelial cell adhesion seems to be the major function responsible 
for leucocyte sequestration, the physical restriction or trapping of leucocytes within capillaries 
may significantly contribute to the leucocyte accumulation observed in the postischaemic liver 
802 18 21 9 220_ Entrapped leucocytes occlude the capillary lumen, and leucocyte-capillary plugging 
will contribute to the development of the "no-reflow" phenomenon in postischaemic tissues. 
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There appears to be a strong correlation between the percentage of no-reflow capillaries and 
the percentage of capillaries containing granulocytes. 
This leucocyte-trapping is due to either ischaemia induced leucocyte deformability and / or 
endothelial cell swelling 221 222 223 . Additional factors might be the accumulation of interstitial 
edema, compressing the microstructure and thereby impeding the movement of blood 
elements within the capillaries 222 224. Compelling evidence for these theories is given by 
studies which either render the recipient neutropenic 225 226, or studies in which the recipient 
receives antibodies affecting the leucocyte-endothelial cell adhesion 226 227 228. In both groups 
the no-reflow phenomenon is virtually abolished . 
Another mechanism of leucocyte accumulation in the postischaemic tissues is a low shear 
rate, wh ich favours leucocyte-endothelial cell adhesion. Several studies show an increase in 
the number of rolling and adherent leucocytes if the shear rate was reduced 229 230 231. 
Adherence of leucocytes by inflammatory mediators is also greatly enhanced by a lower 
shear rate. Electrostatic cell surface charges can also play a role in leucocyte adherence. 
Cationic proteins such a lactoferrin and elastase released from activated neutrophils are 
known to promote neutrophil adhesion 232. 
( ii )Adhesion Molecules 
It has been well established that the adhesion of leucocytes to endothelial cells is mediated 
by various coordinately regulated adhesion glycoproteins expressed on the surface of 
leucocytes, as well as on the surface of endothelial cells 222 233 234. The CD11 / CD18 
glycoprotein complex is rapidly (within 2 minutes) expressed on neutrophils after exposure to 
inflammatory mediators, like L TB4 and PAF. L-Selectin, another leucocyte adhesion 
molecule, is involved in the weak adhesive interactions, manifested as leucocyte-rolling 235. 
P- and E-Selectin are adhesion molecules found on activated endothelial cells. These 
molecules are rapidly mobilized to the cell surface in response to specific stimul i. Histamine, 
thrombin, and hydrogen peroxide lead to the expression of P-selectin in a few minutes, while 
E-selectin is only expressed several hours after being induced by cytokines. 
Both selectins interact with distinct oligo-saccharides on leucocytes to promote "rolling". 
Cytokines also induce an increased expression of the endothelial ICAM-1 adhesion molecule. 
Interaction between endothelial ICAM-1 and leucocyte-CD11/CD18 appears to mediate firm 
adhesion and emigration of leucocytes in post-capillary venules 236. Several experimental 
studies have shown a reduction of up to 95% of reperfusion induced leucocyte adherence and 
leukocyte emigration, after pretreatment with monoclonal antibodies against the adhesion 
molecules on leucocytes, and up to 50% with monoclonal antibodies against adhesion 
molecules on the endothelial cells 237. 
( ii i )Monoclonal antibodies against Adhesion Molecules 
The critical role of leucocyte adhesion in PRI is most clearly demonstrated by protection 
against microvascular and parenchymal cell dysfunction or necrosis by administration of 
monoclonal antibodies directed against adhesion molecules 238. Monoclonal antibodies 
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against leucocyte adhesion molecules appear to offer better protection than antibodies 
directed at the endothelial adhesion molecules 239. Although clinical experience is limited, 
beneficial effects of monoclonal antibodies to ICAM-1 have been reported 240 241 . 
Reactive oxygen intermediates (RO.l's) are released by endothelial cells, as well as activated 
leucocytes, and are able to induce an increase in leucocyte adhesion. Exposure of tissue to 
exogenous hydrogen peroxide (H20 2) or superoxide (02) , promotes leucocyte-endothelial cell 
adhesion 236 242 243. The latter effect of H20 2 seems to be mediated via the formation of PAF, 
while in the superoxide-mediated leucocyte adherence, it seems that nitric oxide might be an 
important factor in the intermediate phase. Nitric oxide is normally produced in the 
endothelium, and might protect against ROI mediated PRI 244. Damaged endothelial cells 
might produce insufficient nitric oxide and therefore cause an increase in cell adhesion. 
It has to be stressed that although adhesion of leucocytes in itself might cause damage due to 
obstruction and induction of the no-reflow phenomenon, the subsequent activation of adhered 
leucocytes is the most likely cause of a greatly amplified inflammatory response 245 246 247. 
Recent research provides evidence that neutrophil-mediated injury to endothelial cells 
involves ROI and protease. While ROl 's appear to be responsible for the initial injury, 
proteases seem to be active after this initial period and for a longer duration 246. The 
adherence of leukocytes is a prerequisite for the endothelial injury by leucocytes. Adhesion 
creates an altered micro-environment within the hepatic sinusoids, in which ROI and 
proteases reach a high concentration and can have their maximum injurious effect. 
The neutrophils responsible for the reperfusion injury seem to accumulate predominantly in 
the sinusoids and in the post-sinusoidal venules. After ischaemia and reperfusion this results 
in immediate microcirculatory changes. Recent, reports indicate that this microcirculatory 
disarrangement might be associated with the subsequent permanent hepatocyte damage and 
mortality 248 249 250. 
(d)Platelet & Procoagulant activity 
( i )Platelets 
Besides leucocytes, platelets also adhere to the hepatic sinusoids immediately after 
reperfusion of cold preserved livers, and the degree of platelet adherence correlates with the 
degree of preservation injury 66 186. Adherence occurs even after heparinization of the 
perfusate, indicating that the adherence is not dependent on a hypercoaguable state. The 
beneficial effects of hepatic glycogenation might also be mediated via the mechanism of 
platelet trapping 119. In experimental studies, animals fed with glucose preoperatively, showed 
significantly less platelet trapping than starved animals. Although there are no human studies, 
recent experimental studies have shown that at least part of the PRI is the result of platelet 
adhesion to sinusoidal endothelial cells 251 . Furthermore, a significant decrease in the extent 
of liver injury has been reported after pretreatment of livers and platelets with PGE1 , a platelet 
adhesion inhibitor 251 . 
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( ii )Clotting and Coagulation Factors 
Several studies have demonstrated an effect of hypoxia on procoagulant activity 252. Hypoxia 
causes suppression of thrombomodulin, as well as synthesis of membrane-associated factor 
X, which promotes coagulation 253. Both leukocyte and platelet adherence indicate an 
alteration of the SLC surface. 
Leucocytes secrete heparinase which degrade heparan sulfate 254 255. Release into the 
circulation of graft proteases upon reperfusion might further activate plasma factors 256 
Activation of PAF, either by Kupffer cells, leucocytes and/or platelets may further induce 
platelet adhesion 257 and enhance the procoagulant environment. Although the exact 
relevance of these mechanisms still have to be elucidated in liver transplantation , a hyper-
coagulable state does occur during and after liver transplantation. Fibrin deposition in hepatic 
sinusoids has been associated with severe primary non-function 66 258. 
The Role of Various Mediators in Reperfusion Injury 
Several important mediators have been shown to play a role in this complex preservation-
reperfusion injury. 
(a)Reactive Oxygen Intermediates 
The term reactive oxygen intermediate (ROI) refers to any compound derived from molecular 
oxygen, that has acquired less than four electrons 259 260 261 . The superoxide anion radical 
(0 2• ) . hydrogen peroxide (H 20 2) and the hydroxyl radical (OH- ). are considered ROl's 
because they have been reduced by one, two and three electrons, respectively. ROl 's have 
been implicated in PRI after warm ischaemia in numerous reports 71 247 262 263 264 265 266 267 as 
well as after cold ischaemia 185 268 269 270. 
It is now well established that the reintroduction of molecular oxygen is required to produce 
the post-ischaemic cellular injury and dysfunction. This supports the view that the PRI is the 
result of the generation of ROI. The production of oxidant species in postischaemic tissues 
has been detected by electron spin resonance (ESR), spectroscopy and ESR spin trapping 
techniques 271 272 273. Metabolites of oxygen-induced peroxidation of cellular membrane lipids 
have been demonstrated on numerous occasions in postischaemic tissues 274 275 276 277 278 279 
280 281
. Malondialdehyde, lipid hydroperoxides and conjugated dienes are the common 
markers for reperfusion-injury. 
The exposure of normal tissues to exogenous oxidant-generating systems produces structural 
and functional changes similar to those observed in postischaemic tissues 263 282 283. 
Moreover, several agents which limit oxidant production, as well as ROI scavengers, are able 
to attenuate the PRI 258 284 285. 
The production of ROI following PRI is the result of the ischaemia on purine metabolism and 
the conversion of xanthine dehydrogenase into xanthine oxygenase 286 287 288 . The enzyme 
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xanthine dehydrogenase, which is found in both parenchymal and endothelial cells, is 
converted into xanthine oxygenase during ischaemia. Recent reports have indicated a major 
role for other ROI sources, such as the NADPH-dependent oxidase system, located on the 
membrane surface of leukocytes and also present in Kupffer cells 262 289 290 291 292 . Inhibition of 
xanthine oxidase as well as neutrophil depletion are both able to reduce PRI 258 274 275 276. After 
the activation of the various enzyme complexes, a respiratory burst occurs upon reperfusion , 
which consumes 90% of the oxygen in the leukocytes 293 and catalyses the reduction of 
oxygen to the hydrogen peroxide and superoxide anion 294 295. 
ROI causes damage to tissues in several ways. One of the main effects is the oxidation of an 
entire array of biomolecules which alter cellular functions 296. Membrane lipid peroxidation, 
DNA-linking and cross-linking, and degradation of proteins 261 284 are all direct results of 
oxidant generation. These molecular changes affect cellular functions by interference with 
structural, contractile and transport proteins, enzymes, receptors, membrane glycolipids, 
glycosaminoglycans and nucleic acids 80• Another proposed mechanism is that superoxide 
radicals may cause the reductive release of iron from ferritin 297 298 299. 
There is also accumulating evidence suggesting that ROI attract and activate inflammatory 
phagocytes 262 300. Chemotaxis is generated if plasma is treated with an oxidant-generating 
system. Also, injection of superoxide-treated plasma or Hypoxanthine-Xanthine-Oxidase into 
the dermis induces massive neutrophil infiltration. Furthermore, oxidant formation contributes 
to the expression of adhesion molecules on the surface of endothelial cells and neutrophils 
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(b)Cytokines 
Many of the effects of various cytokines are very similar to the effects of PRI , while all the 
cells involved in the production of cytokines are present in PRI. The main source for 
cytokines are Kuppfer cells and endothelium adhered leukocytes. Most cytokines act both 
individually as well as in a network of interrelated and interacting signals 302 . The mechanisms 
of action of the numerous cytokines are so complicated that discussing them in detail is 
beyond the scope of this thesis. The proinflammatory cytokine cascade appears to initially 
involve the release of IL-1 and TNF-a.. These cytokines lead to the later production of IL-6 and 
IL-8, increasing infiltration and activation of leukocytes, and eventually the production of IL-4 
and IL-10, which may produce a negative feedback onto the cascade 303 304 305. 
( i )Tumor Necrosis Factor 
TNF activates endothelial cells in several ways. It increases procoagulant activity 306, 
increases leukocyte adhesion, by expressing adhesion molecules on both the endothelial 
cells and the leukocytes 307 308 309 310 and stimulates both ROI release 295 as well as the 
release of IL-1 and IL-8 311 312 . The leukocytes are also activated by TNF resulting in ROI 
generation, aggregation, release of L TB4 , and enhanced phagocytosis 313. TNF might also 
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affect the microcirculation via the production of the endothelial-derived relaxing factor, nitric 
oxide 314. 
( ii )The Interleukins 
IL-I is a pleiotrophic cytokine with similar effects to TNF. Its main source are the activated 
monocytes, especially the Kupffer cells 315. Like TNF-a., it initiates the secretion of other 
cytokines and activates endothelial cells. 
IL-6 is produced by numerous cells, including Kupffer cells and endothelial cells. A major 
activity of IL-6 involves induction of acute phase proteins in hepatocytes, such as C-reactive 
proteins, a.1-antitrypsin and fibrinogen 302 31 6. IL-8 is produced mainly by hepatocytes under 
TNF-a. and IL-1 stimulation 317. It causes PMN-chemotaxis, and may mediate degranulation 
and the respiratory burst in ROI production 312 318. There is no doubt that cytokines are 
responsible for controlling and directing various components of the PRI. 
(c)Proteases 
Proteases are known mediators of PRI in experimental transplant models 319 320. Proteases 
are known to facilitate the generation of ROI by proteolytic activation of XO 321 322, and 
protease inhibitors can inhibit XO, thereby preventing the production of superoxide after 
reperfusion 321 . Both in pig and rat models, the administration to the recipient of the anti-
protease aprotinin had a significant beneficial effect on allograft function and survival. 
Furthermore, anti-proteases added to the cold preservation solution also yielded a positive 
effect on survival 154. Anti-proteases also inhibit coagulation factor activation and the 
production of platelet activating factor (PAF) 256 323. 
(d)Calcium 
Intracellular calcium levels increase due to the release of intracellular depots as well as an 
influx of calcium through the cell membranes. Generally, the cell membrane has a potent 
function of pumping the calcium out of the cell against a 10.000 fold gradient between the 
intra-and extra-cellular space. Furthermore, intracellular free calcium is compartmentalized 
within the mitochondria and the endoplasmatic reticulum 324 . 
After ischaemia and hypothermia, a tremendous influx of calcium occurs into the cell 325. The 
most likely cause for this phenomenon is the failure of the calcium channels and the Na+ / 
Ca++ exchange systems due to decreased energy stores of ATP. ROI cause destruction of 
cell membranes by lipid peroxidation. Calcium influx, therefore, may occur through the 
damaged cell membranes according to the calcium gradient between intra- and extracellular 
space 277. Other possible sources for the increase in the resting cytosolic free-calcium 
concentration are the intracellular organelles, such as the mitochondria 326. The intrahepatic 
calcium concentrations correlate with the severity of the liver injury and the survival in 
experimental models 327. 
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Calcium channel blockers added to the preservation solution significantly ameliorates the PRI 
328 329
. The beneficial effect of calcium channel blockers on reperfusion injury might be 
mediated through different pathways. Several calcium channel blockers have anti-oxidant 
properties 331 . Calcium channel blockers are also well known vasodilators, and this might 
improve the perfusion of the centrilobular regions of the liver, which appear to be the most 
sensitive to hypoxic injury 330. 
A high calcium concentration will potentiate cell damage from ROl 's 331 , as well as enhance 
the conversion of xanthine dehydrogenase (XD) to xanthine oxidase (XO) 332 . Several studies 
have indicated that the rate of hepatocyte apoptosis post transplantation might be related to 
an increase in cytosolic calcium concentration 333 . 
In summary, altered calcium homeostasis appears to be critical in PRI , and recovery from 
intracellular calcium accumulation seems to be crucial for minimizing cellular injury. 
(e)Phospholipase A2 
Although alteration in the calcium homeostasis is strongly implicated in the development of 
hepatocellular injury, the exact working mechanism is unclear. Several theories have been 
proposed. One of the effects of an increased cytosolic calcium concentration involves the 
activation of phospholipase A1, A2 and C 
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. Phospholipase A2 (PLA2) is a key mediator in 
various models of inflammation 335 . It is present in both hepatic endothelial cells and Kupffer 
cells. PLA2 mediates many of the effects credited to cytokines and also mediates most of the 
damaging effects of impaired calcium homeostasis 334 . IL-1 , IL-6 and PAF also appear to 
produce several of their effects through PLA2 activation 
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. PLA2 triggers a multitude of 
processes which include activation of proteolytic enzymes, PAF, eicosanoids, ROI and 
numerous other substances. Experimental studies have shown significantly improved 
mitochondrial function and graft survival when quinacrine (a phopholipase inhibitor) was 
added to the cold preservation solution. The precise role of PLA2 still has to be elucidated. 
(f)Eicosanoids 
Products of arachidonic acid metabolism are produced through either the cyclo-oxygenase 
pathway, producing prostaglandins, prostacyclins and thromboxanes, or the lipo-oxygenase 
pathway, producing leucotrienes. Together these products are called eicosanoids. They are 
produced mainly from Kupffer cells, play an important role as inflammatory mediators and are 
released in high concentration after PRI 337. There is up to a 500-fold increase following OL T, 
and at these levels they may not only have detrimental effects on the graft, but might also 
contribute to cardiovascular, haemostatic and immunological derangements after liver 
transplantation . Not all their effects after OLT are detrimental 81 , since PGE-1 has been used 
to reduce PNF. 
The production of eicosanoids appears to be initiated by ROI release, elevation of the 
intracellular calcium and activation of PLA2. PLA2 triggers eicosanoid production by 
conversion of cell membrane phospholipids into arachidonic acid 325 338 . PAF, TNF and 
endotoxin have also been reported to induce eicosanoids production 339 340. The main effects 
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of eicosanoids classically occur through their action on neutrophils. Neutrophils are potently 
chemo-attracted by L T84 and thromboxanes A2 and 82. Additionally, thromboxane 82 is known 
to activate neutrophil adhesion receptors and has been shown to activate neutrophils to 
produce more ROl 's. Eicosanoids are potent regulators of the blood flow through the 
microcirculation. They have direct effects on the microvasculature and enhance retraction of 
endothelial cells 341 . Alteration of blood flow probably results from an imbalance between 
vasoconstricting and vasodilating eicosanoids 342. 
(g)Platelet Activating Factor 
Platelet Activating Factor (PAF) is an autacoid phospholipid mediator and is thought to be an 
important mediator in the pathogenesis of PRI. Important effects of PAF relevant to PRI are 
the abil ity to prime a variety of leukocyte and macrophage functions. These include the 
respiratory oxygen burst and the release of proteolytic enzymes, TNF and the interleukins.343 
PAF is produced by various cell types: macrophages, neutrophils, lymphocytes, monocytes, 
eosinophils, platelets, endothelial cells and muscle cells 257. PAF is also a potent activator of 
inflammatory cells. It mediates direct interactions between platelets and polymorphonuclear 
leucocytes (PMN) and induces platelet adhesion to endothelial cells if PMN's are present. It 
also induces platelet aggregation 344. It appears that the platelet adhesion is caused by 
activation of PAF-specific membrane receptors on activated PMN's, which then attach the 
platelet-PMN complexes to the endothelium. PAF also stimulates leucocytes and platelets, 
resulting in activation, chemotaxis, chemokinesis, adhesion, aggregation and eventually the 
respiratory oxidant burst 345. In experimental models, the PAF levels have been found to 
correlate with the severity of the hepatic injury and the amount of inflammation post-
transplantation 346. The administration of a PAF-antagonist has been shown to attenuate the 
liver injury and the degree of inflammation 347 348. 
(h)Endothelin 
Endothelin is a family of 21-amino acid-peptides, initially isolated from the supernatant of 
cultured porcine endothelial cells 349. There are several distinct isoforms, wh ich have a wide 
range of biological effects 350 351 . Endothelin-1 (ET-1) is synthesized de nova by endothelial 
cells and is one of the most potent vasoconstrictors. It acts mainly on the venous and arterial 
smooth muscle cells. Its potent effect on vascular tone, together with its rapid clearance from 
the circulation suggests a pivotal role of endothelin in the regulation of regional blood flow 352. 
Elevated levels of endothelin have been associated with a variety of patholog ical conditions, 
includ ing essential hypertension , congestive cardiac failure and transplantation associated 
hypertension 353 354. 
Several experimental studies have suggested an important role for endothelin in liver 
bloodflow. Specific endothelin receptors have been demonstrated on liver plasma 
membranes. Administration of endothelin-1 increases portal hypertension and diminishes 
sinusoidal bloodflow 355. Endothelin-1 antibody injected before reperfusion in a partial warm 
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ischaemia model was able to decrease microcirculatory disturbance, transaminase release 
and biological damage 356 . The use of an ET-1 receptor antagonist has also been proven to 
protect against preservation-reperfusion injury in a pig model 357. There are also a few reports 
documenting the changes in endothelin-1 levels after human liver transplantation 358 359 . 
However the exact pathophysiological role in the clinical situation remains unclear 360. 
Clamping of the portal vein during the transplantation procedure results in bacterial 
translocation 361 and endotoxin is known to stimulate endothelin release , most likely via a 
TNF-a mediated mechanism 362 363. In summary, ET-1 is released from the liver during PRI 
and participates in local and systemic haemodynamic changes. 
(i )Endotoxin 
Thus far, all the factors influencing the severity of PRI discussed above are related to the 
transplanted liver and the duration of cold preservation and warm ischaemia. In contrast, 
endotoxemia is mainly dependent on recipient factors. Endotoxins are known to contribute to 
PRI independent of donor characteristics. However, the preservation damage to the liver will 
be a major determining factor in how the transplanted liver will respond to the endotoxemia. 
The clearance of endotoxin is often deficient in liver transplant recipients due to liver failure 364 
and might be completely absent during the anhepatic period of liver transplantation. The 
reticulo-endothel ial system plays the main role in detoxification of endotoxin. Kupffer cell 
dysfunction due to hypothermia results in higher levels of endotoxins, which persist until the 
donor Kupffer cells are replaced by recipient macrophages. Endotoxin is known to also 
damage hepatocytes 365, to render macrophages cytotoxic 366 and to induce release of a 
variety of biologically active mediators 367. It is also known to enhance the production of ROI 
by Kupffer cells. These effects are most likely mediated by TNF. 
In clin ical transplantation , elevated endotoxin levels preoperatively and at the end of the 
anhepatic period are associated with an increased incidence of graft failure and higher 
mortality 135 368 369 . However, the exact pathogenesis of how endotoxin causes an increase in 
PRI remains unclear. 
Apoptosis 
lschemic injury has been classically described as a coagulative necrosis. In coagulative 
necrosis (or "accidental cell death") large groups of cells are involved and there is a strong 
association with a local inflammatory response. It is a passive, energy-independent process 
370 
Apoptosis or programmed cell death is a tightly regulated , energy-requiring process involving 
the activation of de nova synthesis of endonuclease, resulting in fragmentation of 
internucleosomal double-strand chromatin (DNA) 371 . Apoptotic cells are characterized 
morphologically by blebbing , nuclear and cytoplasmic condensation, subsequent 
disintegration of the nuclear membrane and the formation of multiple fragments of condensed 
nuclear material in the cytoplasm; the so called apoptotic bodies. Apoptosis occurs typically in 
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single cells, which are eliminated by phagocytic cells, without evoking a surrounding 
inflammatory response 372. Reactive oxygen intermediates have been recognized as the 
major mediators of apoptosis 373 374 . The histological and ultrastructural features of apoptosis 
in experimental porcine liver allograft rejection were already noted in 197 4 375. 
Apoptosis has been implicated in cell death following reoxygenation in experimental and 
human studies 376 377. Recently, various techniques including the terminal deoxynucleotidyl 
transferase d-uridine triphosphate nick end labeling, DNA gel electrophoresis and 
transmission electron microscopy, have been used to show that apoptosis of endothelial cells 
might be the pivotal mechanism of preservation injury in liver transplantation 378 379. 
Implications of the double blood supply of the liver for reperfusion 
The liver is unique in that it receives arterial blood from the hepatic artery and venous blood 
from the portal system. Thus, liver blood flow is determined by hepatic artery vascular 
resistance, intra hepatic portal venous vascular resistance and intestinal vascular resistance. 
Each of these factors is variable and dependent on neural and humoral control mechanisms, 
which makes the study of liver perfusion highly complex 380. There appears to be reciprocity 
between the hepatic arterial and portal venous flow in that an increase in blood flow through 
one circuit leads to an increased resistance in the other, thus maintaining a constant flow 
through the liver 381 382. This reciprocity is not only present under physiological 
circumstances, but also in pathological conditions 383. In the classical methods of liver 
transplantation, the portal vein is anastomosed first, and as soon as the anatomosis is 
completed, the liver is reperfused with portal venous blood only. The hepatic arterial 
anastomosis is performed thereafter 384 385 386. 
Originally, this method has been described to minimize the anhepatic period as well as to limit 
the warm ischaemic time. However, in recent years, this classical method of liver 
transplantation has been questioned by several authors. Improved macroscopic perfusion of 
the livers perfused with arterial blood initially has been reported in porcine liver transplantation 
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. This was confirmed by experimental studies in 1994. In rat liver transplantation , the 
number of non-perfused acini and non-perfused sinusoids were reduced by 71 % and 78% 
respectively, if the livers were arterialized simultaneously with portal revascularization 387. 
Several other indicators of PRI were also reduced, including decreased leucocyte 
accumulation in sinusoids and postsinusoidal venules by 17% and 64% respectively 387. 
Additionally, Kupffer cell activation was attenuated, and improved hepatocellular excretory 
function was demonstrated after simultaneous arterialization. 
In 1995, Sankary et al demonstrated that initial portal revascularization was associated with 
an increased number of ischaemic biliary strictures and recommended simultaneous 
revascularization , with the specific aim of avoiding warm bile duct ischaemia 388 . In 1997, a 
clinical study using initial arterialization reported a decrease in PRI 389. Although it might be 
expected that the higher oxygen content of arterial blood would create a greater injury, in fact 
several experimental studies have demonstrated that the major part of the total blood supply 
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to the liver is delivered by the portal blood flow, in spite of its lower oxygen content 390 391 . 
Furthermore, it was reported that both the mean blood transfusion and antifibrinolytic 
requirements, as well as the duration of the post-revascularization phase were reduced. The 
authors concluded that under adequate portal decompression, initial arterialization was a safe 
option and should be recommended 389. A recent clinical study showed a statistically 
significant lower biliary complication rate in simultaneous reperfusion (2%) as compared to 
initial portal venous reperfusion (34%) 392 . 
As discussed earlier, endotoxins do play an important role in PRI. It is well known that the 
endotoxin level of portal venous blood is significantly higher than arterial blood. This 
difference will be even greater in the setting of a malfunctioning spleno-jugular bypass, 
leading to an increase in the portal venous pressure, bowel congestion, and an increase in 
bacterial translocation 
Preservation Solutions and Irrigation Solutions 
Eurocollins Solution 
Studies in the late 1960's demonstrated that kidneys could be safely preserved for 30 hours 
by simple cold storage only and for up to 72 hours by continuous perfusion 93 95 . The original 
paper from Collins 95, in which he showed that cooled kidneys could be preserved for up to 3 
times longer if treated with the appropriate preservation solution, rather than with cold blood, 
compared already seven different preservation solutions. Eurocollins was also used as the 
preservation solution fluid in liver transplantation 99 393 . With Eurocollins solution, the livers 
could be stored for up six hours. The advantages of prolonged storage were rapidly realized 
and the search for new preservation solutions followed 394 395 396 397. 
The University of Wisconsin Solution 
Extensive research during the 1980's into the mechanisms underlying reperfusion injury led to 
the development of the "University of Wisconsin Solution" or "UW-solution". This solution was 
developed by Folkert Belzer purely on empirical grounds 99. This solution was first used to 
preserve the canine pancreas for 72 hours 398 . Subsequently, successful storage of the 
canine liver for 24 and 48 hours in experimental liver transplantation was reported 399. This 
was followed by the report in March of 1988 of the use of UW solution in human liver 
transplantation. Tolerance for cold ischaemia was significantly improved from 8 hours or less 
with Collins' solution to over 20 hours 400. The 12 constituents in UW solution were all added 
to counter balance specific metabolic processes thought to be responsible for preservation 
injury.(Table 2.1) 
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The success of cold storage is primarily related to the prevention of tissue oedema. The most 
important contributions of UW solution are lactobionate and raffinose as impermeants to 
suppress hypothermia induced tissue swelling 400. Lactobionate is a large sized organic anion, 
which by nature of its size and negative charge, is impermeable to most tissue membranes. 
Raffinose, a trisaccharide, and hydroxyethyl starch, were both added for additional osmotic 
support, and to prevent expansion of the extracellular space. The phosphate buffer was 
added to the solution to prevent tissue acidosis, which is induced by the anaerobic 
metabolism from the ischaemic cells. 
Table 2.1 
Composition of University of Wisconsin (UW) Solution 
Component Amount 






Allopurinol 1 mM 
Dexamethasone 16 mg 
Regular Insulin 40 U/L 
Penicillin G 200 000 U/L 
Hydroxyethylstarch 50 g/L 
Osmolarity 320 mOsm/L 
Solution is brought to Ph 7.4 at room temperature with NaOH. 
Adenosine and phosphate were added as precursors for ATP-production as well as to support 
energy-utilizing reactions 401 . Allopurinol and glutathione were added with the specific goal of 
preventing toxic oxygen radical related damage. Allopurinol is a well known inhibitor of the 
xanthine oxidase, while glutathione is known for its toxic oxygen radical scavenging capacity. 
As stated earlier, the development of UW solution was purely theoretical and it is therefore 
not surprising that several modifications have not altered its excellent performance. 
Hydroxyethyl starch has been omitted without negatively influencing the preservation injury 137 
402 403. Other substances like raffinose, lactobionate and glutathione can not be omitted 
without negative effects 404. The Potassium salts have been replaced successfully by sodium 
salts 405 406. In spite of numerous possible modifications, UW solution remains currently the 
gold standard cold preservation solution 407 408 409 410. 
30 
HTK (Bretschneider) Solution 
Originally, Bretschneider developed this solution specifically to provide myocardial protection 
during the cardioplegic period 411 412. He considered the primary goal of any myocardial 
protection solution to be the reduction of the myocardial energy demand. Since survival of the 
non-perfused tissue depends on ongoing anaerobic metabolism with resulting tissue acidosis, 
he postulated that any cardioplegic solution should contain a substance with a high buffering 
capacity even at low temperatures. He used the physiologic protein buffer histidine to fulfill 
this role. He also recognized the importance of the delivery of energy substrates in the 
myocardial protection solutions, and therefore ketoglutarate and tryptophane were added . 
These substances are able to produce ATP, while inhibiting glycolysis and reducing lactate 
production and tissue acidosis. Potassium was added to achieve cardiac arrest, while 
magnesium was added to reduce calcium efflux and stabilize ionic membrane status. 
Mannitol was chosen as an agent to increase the osmotic gradient and to prevent tissue 
oedema. Since this solution is based on its substantial buffering capacity and is described as 
an "equilibrium" solution, high volume flush-outs are used allowing equilibration across the 
cell membrane 413.This may have the additional advantage of rapid core cooling . Contents of 
the Bretschneider - HTK4 solution are shown in table 2.2. 
After successful introduction in kidney transplantation , HTK solution has also been used in 
liver transplantation 41 4 415. Several European centers have introduced HTK solution in their 
liver transplantation program. The interim results of a multicenter trial performed in Germany 




























In view of the pivotal role of reactive oxygen intermediates in preservation-reperfusion injury, 
several new solutions have been developed to counteract oxidation. In 1994 a new 
cardioplegic solution, Celsior, was introduced (Table 2.3) 417 418. Experimental evaluation 
using both isolated heart and heterotopic transplantation , showed that this solution had 
protective effects. The major feature of Celsior is the presence of three anti-oxidants, 
reduced glutathione 419 420, mannitol 421 and histidine 422 . The primary target of Celsior is 
prevention of free radical injury, which remains an important cause of early graft dysfunction 
423 424 425 426 427
. Reduced glutathione, a powerful anti-oxidant is one of the constituents of 
Celsior. Unlike other solutions, in which shelf-storage of glutathione will lead to oxidation and 
development to its potentially cardiotoxic form, Celsior has been specifically designed to allow 
delivery of a predominantly reduced form of glutathione 420 428. Additional antioxidant effects 
are provided by mannitol and histidine because of their capacity to scavenge hydroxyl 
radicals 421 . Celsior has mainly been used in cardiac surgery and transplantation. At present 
there is evidence demonstrating a decrease in reperfusion injury in other solid organ 












pH (at 20°c) 
Osmolarity 
Table 2.3 











41 .5 mM 
7.3 
360 mOsm/L 
* To avoid oxidation of reduced Glutathione, the latter compound is prepared under anaerobic 
conditions and stored in 5-ml deaerated glass syringes, the content of which is added to the 
plain Celsior solution immediately before use. 
Although a pharmacologic approach to organ preservation solution development might lead 
to significant improvements in graft function , Southard 430 warns that the use of pharmacologic 
agents in preservation solutions is fraught with difficulties. These agents are often inactive at 
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storage temperatures, have poor permeability, and may be rapidly washed away upon 
reperfusion . Furthermore, PRI involves multiple sites requiring multiple pharmacological 
agents. 
Irrigation Solutions 
Because of the high potassium contents as well as the presence of adenosine in the UW 
solution, it is necessary to rinse out the UW solution from the liver graft prior to 
revascularization 431 . Ringer's lactate is especially suitable because of its similarity to the 
extracellular fluid . Several studies have shown that the use of warm Ringer's lactate flush 
has an advantage over a cold rinse 432 433. If cold Ringer's lactate is used, it is preferable to 
reflush with warm portal blood, and to discard the first 300-400 ml of portal blood 434. The use 
of 4% serum albumin as a rinse solution has been shown to compare favourably with the use 
of Ringer's lactate 435. 
Carolina Rinse Solution 
Recently, a complex rinse solution has been developed with the specific aim of minimizing 
reperfusion injury and improving graft survival (Table 2.4)436 437. The Carolina Rinse Solution 
consists of 10 empiri~I components, including adenosine, nisoldipine, desferrioxamine and 























Solution is brought to pH 7 .4 at room temperature with Na OH 
Adenosine is able to improve survival by inhibiting platelet-aggregation 439, diminishing 
Kupffer cell activation 436 438, improving micro circulation 440 and by its conversion to ATP 436 441 
442. This solution has since been modified by the addition of allopurinol , and glutathione to 
further reduce the sinusoidal reperfusion injury 443. Clinical trials have demonstrated that 
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Carolina rinse solution is more effective in reducing cholestatic injury rather than in 
decreasing hepatocellular damage 444. The exact role of the rinse solution in human liver 
transplantation is not yet known , although there are indications that it improves graft function 
445
. The most significant benefit of a rinse solution may well be a short rewarming period, just 
prior to reperfusion , with subsequent improvement of the microcirculation 66 432 433. 
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CHAPTER3 
Hypothesis and Study Design 
The preservation-reperfusion injury (PRI) in liver transplantation has been extensively 
documented, and has been identified as an important cause of both primary non-function and 
delayed function of the liver graft. Thus any interventions which minimise the PRI would have 
a significant impact on the results of liver transplantation . 
In addition, the liver is peculiar in that it has dual blood supply, with arterial blood via the 
hepatic artery and venous blood via the portal vein. 
Hypothesis 
1. In liver transplantation , the reperfusion injury associated with portal venous 
revascularization is different from that associated with hepatic artery revascularization . 
2. In liver transplantation , early rearterialization of the liver allograft is associated with a 
lesser reperfusion injury. 
3. The use of Celsior as a preservation solution in liver transplantation , because it contains 
several free radical scavengers, is associated with a lesser reperfusion injury, compared 
to the University of Wisconsin Solution . 
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Study Design 
Experiment 1: Reperfusion injury associated with portal venous and hepatic arterial 
reperfusion 
Large White X Landrace pigs were subjected to orthotopic liver transplantation and randomly 
allocated to either portal venous revascularization (PV) 20 minutes before hepatic arterial 
revascularization (HA), or HA 20 minutes before PV. Blood samples were taken before and 
after PV, before and after HA, and after total revascularization . 
Experiment 2: The effect of early rearterialization of the liver allograft on reperfusion 
injury, hepatocellular injury and endothelial cell dysfunction 
Large White X Landrace pigs were subjected to orthotopic liver transplantation and randomly 





PV 60 minutes before HA. 
PV 20 minutes before HA. 
Simultaneous HA and PV. 
HA 20 minutes before PV. 
Blood samples were taken before and after PV, before and after HA, and after total 
revascu I a rizatio n. 
Experiment 3: Histological assessment after different modes of reperfusion after liver 
transplantation 
Large White X Landrace pigs were subjected to orthotopic liver transplantation and randomly 
allocated to the groups as described in Experiment 2. Liver biopsies were taken after 
dissection of the donor liver (base) , after the cold storage period , and one hour after 
completed reperfusion . 
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Experiment 4: The effect of Celsior, Wisconsin and Eurocollins Solution on the 
hepatocellular, reperfusion and endothelial cell injury 
Large White X Landrace pigs were subjected to orthotopic liver transplantation and the livers 
stored in the following preservation solutions: 
Group 1: Eurocollins solutions. 
Group 2: 
Group 3: 
University of Wisconsin Solution. 
Celsior solution. 
Blood samples were taken at various time intervals after total revascularization . 
Biochemical analyses 
The blood samples were subjected to the following analysis: 
Serum AST 
Plasma malondialdehyde 
Serum vitamin A 
Serum hyaluronic acid 
Histology 
The liver biopsies were subjected to routine histological examination . 
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CHAPTER4 
Reperfusion Injury Associated with Portal 
Venous and Hepatic Arterial Perfusion in Liver 
Transplantation 
Summary 
Although reperfusion injury in organ transplantation is presently well established, its exact role 
in liver transplantation still has to be defined. 
The aim of this part of the study was to document the reperfusion injury associated with 
porcine liver transplantation and to evaluate the different components of the reperfusion injury 
associated with arterial and portal reperfusion. 
Large White X Landrace pigs were randomized into 2 groups. Group 1: Initial portal 
reperfusion and Group 2: initial arterial reperfusion. Several indicators of reperfusion injury, 
endothelial cell function and hepatocellular damage were assessed. 
Malondialdehyde concentrations were lower and Vitamin A concentrations were higher in the 
animals subjected to initial arterial reperfusion . Serum AST and serum hyaluronic acid 
concentrations both were higher in the animals subjected to initial portal reperfusion . 
Results of this study indicate that the major part of reperfusion injury is constituted during the 
portal venous reperfusion and that this injury can be, at least partially, attenuated by initial 
arterial reperfusion. 
Introduction 
Liver transplantation is now established as the treatment of choice for most patients with 
chronic end stage liver disease and is performed routinely in most major centres throughout 
the world . During the transplantation process, the liver allograft may be injured in several 
ways, including the preservation-reperfusion injury, rejection, infection and drug toxicity. The 
extent of the preservation-reperfusion injury may vary from mild, causing minimal hepatic 
dysfunction, to severe, leading to primary non-function. 
Despite the major advances in clinical liver transplantation , including the development of the 
University of Wisconsin cold preservation solution, the preservation-reperfusion injury 
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continues to be a serious problem and a significant cause of post-transplant hepatic 
dysfunction 446 . The pathophysiology involved in the preservation-reperfusion injury and the 
possible preventative modalities have been extensively documented 446 447 448 449. However, 
the relative contribution of the portal blood and the hepatic arterial blood to the reperfusion 
injury has not been investigated previously. 
The conventional technique of liver transplantation involves initial reperfusion of the allograft 
with portal blood followed some time later by hepatic arterial reperfusion (Group I). To 
evaluate the reperfusion injury associated with hepatic arterial reperfusion, we reversed the 
order of the anastomoses in Group 2. 
The reperfusion injury is thought to be mediated, at least in part, by the formation of reactive 
oxygen metabolites 262 263. The latter are responsible for damage to an array of bio-molecules, 
including membrane lipids, enzymes and receptors. The peroxidation of the membrane lipids 
results in the formation of malondialdehyde (MDA) and other conjugated dienes. Thus MDA 
can be used as a marker of the reperfusion injury. Endogenous vitamin A is an important 
scavenger of reactive oxygen metabolites, and the serum levels can also be used as an 
indicator of the reperfusion injury. 
Hyaluronic acid (Ha) is synthesized mainly by mesenchymal cells and is rapidly removed and 
degraded primarily by hepatic endothelial cells 157. Normally, the concentration of Ha is low. 
However, impaired catabolism by hepatic endothelial cells results in elevation in a porcine 
liver transplant model 450. 
Amino Aspartate Transferase (AST) is a well established marker for hepatocellular injury. 
The reperfusion injury of the liver caused by the formation of reactive oxygen species has 
been extensively documented in experimental systems 66. There is however, only limited 
evidence for its occurrence following liver surgery in humans. In addition, the liver is unique 
in that it has a dual blood supply, and the relative contribution of the portal and hepatic arterial 
blood to the reperfusion injury has not been investigated previously. Thus, the aim of this 
study was to document the reperfusion injury associated with liver transplantation in the pig 
and to evaluate the reperfusion injury associated with portal venous and hepatic arterial 
reperfusion . 
Materials and Methods 
This study was approved by the Animal Research Review Committee of the University of 
Cape Town. Young Large White X Landrace pigs (n=12) of either sex and weighing 20 - 30kg 
were fasted overnight. Anaesthesia was induced with intravenous thiopentone sodium (2 
mg/kg) administered via an ear vein , and maintained with nitrous oxide and oxygen given via 
an endotracheal tube. Catheters (French 8) were introduced into the common carotid artery, 
for monitoring of blood pressure and for sampling of arterial blood, and into the jugular vein , 
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for the infusion of intravenous fluids. The technique of orthotopic liver transplantation was as 
described previously 451. 
Donor Operation 
The preparation of the donor liver involved dissection and mobilization of the suprahepatic 
and infrahepatic vena cavae, the portal vein, the hepatic artery and the bile duct in the hilum 
of the liver. The animal was heparinized and a catheter inserted into the portal vein for initial 
flushing of the liver with ice-cold Eurocollins solution. Although the common practice is to use 
University of Wisconsin solution , we decided to use Eurocollins solution to reduce the costs of 
the experiments. The liver was excised during the in situ flushing which was continued on the 
back-table. 
The donor liver was stored in ice-cold Eurocollins solution (4 degrees Celsius) for three hours, 
since prolonged storage time is associated with a high mortality in the pig liver transplantation 
model. 
Recipient Operation 
The dissection of the recipient liver was as described above. After heparinization of the 
an imal, the passive splenojugular venous bypass between the splenic vein and the external 
jugular vein was established . The recipient liver was excised, and the donor liver implanted 
as follows: 
Group 1 (n=6): The anastomosis of the suprahepatic vena cava, the infrahepatic vena cava 
and the portal vein were completed first; at this stage these vessels were 
undamped and the liver perfused with portal blood only; thereafter the hepatic 
arterial anastomosis was completed and total reperfusion of the liver 
achieved . 
Group 2 (n=6): The suprahepatic vena cava, the infrahepatic vena cava and the hepatic 
artery were anastomosed first; these vessels were undamped and the liver 
perfused with arterial blood only; thereafter the portal venous anastomosis 
was performed and total reperfusion of the liver achieved. 
In both groups, the donor bile duct was anastomosed end-to-end to the recipient bile duct. 
The time at which the liver was reperfused with both portal venous blood as well as arterial 
blood was set as the zero point ("O minutes") and time was calculated from there to before 
(negative time scale) and to after completed reperfusion (positive time scale) . 
Previous studies have shown that the first hour is the most sensitive period to demonstrate 
alterations in the reperfusion injury markers. Thus, blood samples were taken preoperatively, 
at 5 minutes before (-25 minutes in group 1 and -5 minutes in group 2) and 5 minutes after 
portal reperfusion (-15 minutes in group 1 and 5 minutes in group 2) , and at 5 minutes before 
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(-25 minutes in group 2 and -5 minutes in group 1) and 5 minutes after hepatic arterial 
reperfusion (-15 minutes in group 2 and 5 minutes in group 1 ), and at 20, 40 and 60 minutes 
after total reperfusion for assessment of the reperfusion injury markers plasma 
malondialdehyde and serum vitamin A 
The hepatocellular injury related to the reperfusion injury was determined in the first 24 hours. 
Blood samples were taken preoperatively and at 1 hour, 2 hours and 4 hours post 
transplantation for serum AST levels as a marker of the hepatocellular injury. 
The marker for endothelial cell function, serum hyaluronic, was also measured in the first hour 
(at base, at 5, 20, 40 and 60 minutes post reperfusion) . 
Plasma Malondialdehyde (MDA) levels were determined by the thiobarbituric assay as 
described by Lepage 452 . 2-Thiobarbituric acid (TBA) was added to deproteinized plasma and 
the reaction between the MDA and TBA, under conditions of low pH and high temperature, 
yielded a chromogenic adduct that was detectable by fluorometry. 
Serum Vitamin A levels were measured fluorometrically, according to the original method 
described by Thompson 453. Vitamin A, which fluoresces in ultraviolet light, was first extracted 
into water and ethanol, then into hexane and detected by fluorometry. 
Serum Hyaluronic Acid (Ha) levels were estimated by radioimmunoassay using a kit 
purchased from Kabi Pharmacia 454. 125 I-labeled Hyaluronic Acid binding protein (HABP), 
isolated from bovine cartilage, was used to bind the Ha in the sample. The unbound 125 1-
HABP was quantitated by incubating with Ha covalently coupled to Sepharose particles . 
Separation was performed by centrifugation and decanting. The radioactivity bound to the 
particles was read in a gamma counter which was inversely proportional to the concentration 
of Ha in the sample. 




Plasma malondialdehyde (Figure 4.1) . 
There was an increase in plasma MDA levels from 2.53 µmol/1 preoperatively to 5.64 µmol/1 
after portal reperfusion in Group 1. Hepatic arterialization in these animals was associated 
with a slight decrease in MDA levels from 4.73 µmol/1 to 4.06 µmol/1. Thereafter plasma MDA 
levels continued to decrease and were almost back to baseline levels by 60 minutes after 
total reperfusion. 
In the animals in Group 2 which received arterial blood to the allograft first, plasma MDA 
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Arterial levels of Malondialdehyde (µmol/1) from 25 minutes before completion 
of revascularization up till 60 minutes after completion. 
(Group 1 = initial portal reperfusion ; Group 2 = initial arterial reperfusion) 
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Serum vitamin A (Figure 4.2) . 
The serum vitamin A levels decreased from 18. 7mg/l to 9.6 mg/I after portal reperfusion in the 
animals in Group 1. Serum vitamin A levels remained unchanged after subsequent arterial 
reperfusion and remained markedly decreased up to 60 minutes after total reperfusion. 
In the animals in Group 2, initial arterial reperfusion was associated with a minimal decrease 
in serum vitamin A levels. There was a further decrease in vitamin A levels after portal 
















-15 -5 5 20 40 60 
tJ Group 1 • Group 2 I 
Arterial levels of Vitamin A, (mg/I) from 25 minutes before till 60 minutes 
after completion of revascularization. 
(Group 1 = initial portal reperfusion; Group 2 = initial arterial reperfusion) 
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Serum AST (Figure 4.3) . 
There was a significant increase in serum AST levels at one hour after total reperfusion in 
both groups of animals. Thereafter, serum AST levels in the animals in Group I continued to 
increase up to 4 hours after total reperfusion . In contrast serum AST levels remained 
unchanged after the first hour in the animals in Group 2. There was no significant difference 
between the AST levels at 4 hours. 
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Peripheral venous levels of AST (IU) post transplantation at various times. 
(Group 1 = initial portal reperfusion ; Group 2 = initial arterial reperfusion) 
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Serum Hyaluronic Acid (Figure 4.4). 
There was a significant increase in serum Ha levels at 5 minutes after total reperfusion in both 
groups of animals. The serum Ha levels in the animals in Group 2 were starting to decrease 
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Hepatic venous levels of Hyaluronic acid (µg/1) after transplantation at various 
times. 
(Group 1 = initial portal reperfusion; Group 2 = initial arterial reperfusion) 
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Discussion 
In this study, initial reperfusion of the hepatic allograft with portal blood was associated with a 
marked reperfusion injury, as evidenced by an increase in plasma MDA levels and a 
decrease in serum vitamin A levels. Subsequent arterialization of the liver in these animals 
did not attenuate the reperfusion injury, with plasma MDA and serum vitamin A levels 
remaining unchanged. In contrast, initial reperfusion of the hepatic allograft with arterial blood 
was not associated with a reperfusion injury, since plasma MDA levels remained unchanged 
and serum vitamin A levels decreased only slightly. In these animals, subsequent perfusion 
of the allograft with portal blood did not result in a reperfusion injury (plasma MDA levels 
unchanged and vitamin A slightly decreased). 
In the present study, serum Ha levels continued to increase up to 60 minutes after total 
reperfusion in the animals perfused with portal blood first and were decreasing by 60 minutes 
in the animals perfused with arterial blood first. This supports the finding of a greater 
reperfusion injury in livers perfused with portal blood first. 
Serum AST levels, although similar in the first two hours after total reperfusion, were slightly 
higher at 4 hours in the animals perfused with portal blood first, indicating a greater amount of 
hepatocellular injury in these animals. 
Thus, in summary, there was a significant reperfusion injury associated with portal reperfusion 
of the allograft, especially if this occurred before arterialization. There was no evidence of a 
reperfusion injury after arterial reperfusion , irrespective if this occurred before or after portal 
reperfusion . Furthermore, initial arterial perfusion of the allograft appeared to protect the liver 
from the reperfusion injury associated with portal reperfusion . 
The reasons for the difference in the reperfusion injury associated with portal and arterial 
perfusion of the allograft remain unclear. One would expect a greater reperfusion injury after 
arterial perfusion because of its higher oxygen content. However, several studies indicate 
that the major part of the total oxygen supply to the liver is delivered by the portal blood, even 
though its oxygen content is lower 455. 
The advantage of initial arterial perfusion may be due to the improvement in the micro-
circulation of the graft associated with early arterialization, as shown previously in 
experimental studies 387. 
Furthermore, the endotoxin level of portal venous blood is significantly higher, especially if 
mesenteric venous congestion occurs in the setting of a malfunctioning splenojugular bypass. 
Endotoxins are known to damage hepatocytes 456 , to render Kupffer cells cytotoxic and induce 
release of a variety of biological active mediators 367. It is also known to enhance the 
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production of reactive oxygen intermediates by Kupfter cells. Also, in clinical transplantation 
elevated endotoxin levels preoperatively and at the end of the anhepatic period have been 
associated with graft failure and an increased mortality 368 457. 
Conclusion 
This study shows that in liver transplantation initial reperfusion of the allograft with portal 
blood was associated with a marked reperfusion injury and no additional injury after 
subsequent arterialization. 
Furthermore, initial arterialization of the liver allograft was not associated with a marked 
reperfusion injury and protected the liver against the reperfusion injury following subsequent 
portal reperfusion . 
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CHAPTER 5 
The Effect of Early Arterialization of the Liver 
Allograft on Reperfusion Injury, Hepatocellular 
Injury and Endothelial Cell Dysfunction 
Summary 
The conventional technique of liver transplantation involves initial perfusion of the graft with 
portal blood. However, recent evidence suggests that initial arterialization of the graft may be 
better. The aim of this part of the study is to evaluate the timing of arterialization on the 
reperfusion injury, hepatocellular injury and endothelial cell function after liver transplantation. 
Large White X Landrace pigs (n=24) were subjected to orthotopic liver transplantation. The 
animals were randomized into 4 groups ranging from late arterialization (60 minutes after 
portal reperfusion) to early rearterialization (20 minutes before portal reperfusion) . 
AST levels continued to rise 4 hours post transplant in group 1 (late arterialization), but 
remained stable after 1 hour post transplant in group 4 (early rearterialization). Levels of 
malondialdehyde doubled in all groups after portal reperfusion , with the exception of group 4, 
in which the liver received arterial blood before portal reperfusion . Vitamin A levels decreased 
in all groups after revascularization , but the decrease was more pronounced and prolonged in 
group 1 and 2 (late arterialization) as compared to group 3 and 4 (early rearterialization). 
Hyaluronic acid levels continued to rise in all groups until 1 hour post transplant, except in 
group 4, where the level already decreased from 20 minutes post transplantation. 
Results of this study show that early rearterialization is associated with less hepatocellular 
damage, less reperfusion injury and improved liver endothelial cell function . In conclusion , our 
results indicate that early rearterialization of the graft is beneficial to the transplanted liver. 
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Introduction 
In clinical liver transplantation, reperfusion of the graft occurs after completion of the vena 
caval and portal venous anastomoses 384 385. Originally this was done to keep the portal 
occlusion time as brief as possible. However, despite the use of the porto-systemic veno-
venous bypass to overcome the problems of portal occlusion, the portal vein is still 
anastomosed first 386. The rationale for this was to shorten the anhepatic period and to 
minimize the rewarming of the ischaemic graft. The arterial anastomosis was performed 
thereafter, leading to a variable period, depei1ding 0n the difficulty of the dissection of the 
artery, during which the graft was perfused by portal blood only. 
However, in recent years, concerns have been expressed about the delay in performing the 
arterial anastomosis 388 458. Several experimental and clinical studies have shown beneficial 
effects in liver grafts perfused with arterial blood first 173 387 389. However, quantitative 
evidence of the advantage of early rearterialization has been limited. 
In this study, we investigated the impact of the timing of the arterial anastomosis on the 
hepatocellular injury, the reperfusion injury, and the endothelial cell function after liver 
transplantation. 
Materials and Methods 
The experimental protocol was approved by the Animal Research Review Committee of the 
University of Cape Town . Twenty-four young Large White X Landrace pigs of either sex and 
weighing 20--20 kg were fasted overnight 8nd r,.!1:~esthetized with intravenous s.)d ium 
thiopentone (2mg/kg) . Anaesthesia was mair.tained with nitrous oxide and oxygen 
administered through an endotracheal tube. Catheters (Fr8) were inserted into the common 
carotid artery, for monitoring of blood pressure and for sampling of arterial blood, and into the 
internal jugular vein for the infusion of intravenous fluids. The animals were subjected to 
orthotopic liver transplantation using the technique described previously 451 . 
Donor Operation 
The abdomen was explored via a midline incision extending from the xiphisternum to the 
symphysis pubis. After the hilar dissection and mobilization of the suprahepatic and 
infrahepatic vena cava, the animal was heparinized and a catheter inserted into the portal 
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vein for initial flushing . Eurocollins solution was used in stead of University of Wisconsin 
solution to reduce costs. The liver was then excised during in situ flushing with ice-cold 
Eurocollins solution through the portal vein . Flushing of the liver with Eurocollins solution was 
continued on the back-table. 
Storage 
The donor liver was placed in a plastic bag with Eurocollins solution and stored on ice for 
three hours, since long storage times are associated with a poor survival in the liver 
transplantation model. 
Recipient Operation 
The preparation of the liver was as described above. After the dissection of the hilum of the 
liver and the suprahepatic and infrahepatic vena cavae, the animal was heparinized and the 
passive spleno-jugular venous bypass established . The recipient liver was excised, and the 
donor liver implanted by anastomosing the suprahepatic vena cava, infrahepatic vena cava, 
portal vein , hepatic artery and bile duct. 
The animals were randomly allocated to the following treatments groups according to the 
order of the vascular anastomoses: 
Group 1 (n=6): 
Group 2 (n=6): 
Group 3 (n=6): 
Group 4 (n=6): 
hepatic arterial perfusion 60 minutes after portal perfusion (PV-60-HA). 
hepatic arterial perfusion 20 minutes after portal perfusion (PV-20-HA). 
hepatic arterial perfusion simultaneous with portal perfusion (HA-PV). 
hepatic arterial perfusion 20 minutes before portal perfusion (HA-20-PV). 
Perioperative Management 
During the operation the animals received an infusion of Plasmalyte B with added dextrose 
and 300 ml of donor blood to maintain haemodynamic stability. Postoperatively the pigs were 
returned to warmed cages and intravenous infusion continued for two days. 
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Blood sampling and assays 
The moment of completed venous and arterial blood supply and the start of reperfusion 
th rough the liver through both vessels was set a moment zero, and times of sampling were 
calculated from there. (Negative values before reperfusion , positive values after 
revascularization.) The transplantations were performed in such a fashion, that this moment 
"zero" was exactly 3 hours post storage, to reduce an error in results due to variable ischemic 
times. Details about the various sampling times are stated in Table 5.1. 
Group 1 Group 2 Group 3 Group 4 
-65 minutes Sample 
-60 minutes Portal 
Re perfusion 
-55 minutes Sample 
-25 minutes Sample Sample Sample 
-20 minutes Portal Arterial 
Re perfusion Re perfusion 
-15 minutes Sample Sample Sample 
-5 minutes Sample Sample Sample Sample 
Zero Arterial Arterial Arterial and Portal 
Reperfusion Reperfusion Portal Re perfusion 
Re perfusion 
+5 minutes Sample Sample Sample Sample 
+20 minutes Sample Sample Sample Sample 
+40 minutes Sample Sample Sample Sample 
+60 minutes Sample Sample Sample Sample 
+ 2 hours Sample Sample Sample Sample 
+ 4 hours Sample Sample Sample Sample 
Table 5.1 Blood sampling times in the four different groups. 
Blood samples for AST's were taken from catheter in a peripheral vein , at baseline, 1 hour, 2 
hours and 4 hours after completed transplantation. Blood samples for assessment of 
Hyaluronic acid were taken from a catheter in the hepatic vein , at baseline, 5, 20, 40 and 60 
minutes after completion. Assessment of Malondialdehyde and Vitamin A was performed on 
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arterial blood samples, taken at 5 minutes before and after portal venous reperfusion , as well 
as 5 minutes before and after arterial reperfusion . 
Plasma Malondialdehyde (MDA) levels were determined by the thiobarbituric assay as 
described by Lepage 452 . 2-Thiobarbituric acid (TBA) was added to deproteinized plasma 
and the reaction between the MDA and TBA, under conditions of low pH and high 
temperature, yielded a chromogenic adduct that was detectable by fluorometry. 
Serum Vitamin A levels were measured fluorometrically, according to the original method 
described by Thompson 453. Vitamin A, which fluoresces in ultraviolet light, was first extracted 
into water and ethanol , then into hexane and detected by fluorometry. 
Serum Hyaluronic Acid (Ha) levels were estimated by radioimmunoassay using a kit 
purchased from Kabi Pharmacia 
454
. 125 I-labeled Hyaluronic Acid binding protein (HASP), 
isolated from bovine cartilage, was used to bind the HA in the sample. The unbound 125 1-
HABP was quantitated by incubating with HA covalently coupled to Sepharose particles. 
Separation was performed by centrifugation and decanting. The radioactivity bound to the 
particles was read in a gamma counter which was inversely proportional to the concentration 
of Ha in the sample. 




The mean AST levels pre-operatively were similar in all four groups. There were significant 
increases in serum AST at one hour after total reperfusion , from 61±36 to 469±.118 iu in group 
1, 55±34 to 336±1 96 iu in group 2, 72±37 to 361±94 iu in group 3, and from 48±24 to 
434±198 iu in group 4. The serum AST levels at 4 hours were highest in group 1 (925±234 iu) 
and lowest in group 4 (464±120 iu). This difference at 4 hours between the group 1 and the 
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Arterial levels of serum AST at base, 1, 2 and 4 hours post transplantation in 
international units at various times. 
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The preoperative plasma malondialdehyde levels were similar in all 4 groups. There was a 
marked, but not statistically significant, increase in plasma malondialdehyde levels associated 
with portal reperfusion in the animals in groups 1, 2 and 3. However, plasma 
malondialdehyde levels remained unchanged in the animals in group 4 which received arterial 
blood 20 minutes before portal reperfusion. There was no further rise in malondialdehyde 
levels after portal revascularization . At 60 minutes after total reperfusion plasma MDA levels 













A rte r i a I M a Io n d i a Id e h y d e 
-55 -25 -15 -5 5 20 40 60 
!-+-group 1 - group 2 --6-- group 3 --M- group 4 i 
Arterial Malondialdehyde concentrations during and after liver transplantation 
in micromols/liter at various times in minutes. 
Group 1 Group 2 Group 3 Group 4 
- 60 minutes Venous 
reperfusion 
- 20 minutes Venous Arterial 
re perfusion reperfusion 
zero Arterial Arterial Arterial and Venous 
reperfusion re perfusion venous reperfusion 
reperfusion 
Arterial and venous reperfusion times in the various groups. 
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In the animals in groups 1 and 2, which received portal blood before arterial blood, portal 
reperfusion was associated with a decrease in serum vitamin A levels and levels remained 
low for the duration of the study. In contrast the vitamin A levels in the animals in groups 3 
and 4, which received arterial blood before or simultaneous with portal reperfusion , remained 
elevated for the duration of the study. Vitamin A levels were significantly higher after portal 
reperfusion in the animals in groups 3 and 4, compared to those in groups 1 and 2. 
Arterial Vitamin A levels after liver transplantation 
25 
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The baseline serum hyaluronic acid (Ha) levels were similar in all four groups. There was a 
significant increase in Ha levels in all four groups of animals (p<.00001). There were no 













Hepatic vein hyaluronic acid levels post 
transplantation 
baseline 5 20 40 
I-+- group 1 --- group 2 -6- group 3 """*- group 41 
60 
Serum Hyaluronic acid levels at base up to 60 minutes post transplantation in 
microgram/I at various times in minutes. 
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Discussion 
The standard technique of liver transplantation involves initial reperfusion of the graft with 
portal blood followed by arterial perfusion. The delay in arterialization of the graft could vary 
from about 20 minutes to beyond one hour, depending on the difficulty of the arterial 
dissection or whether an arterial conduit is needed. This order of revascularization has been 
questioned in recent years. One clinical study comparing liver allografts rearterialized soon 
after portal reperfusion with delayed rearterialization failed to show any difference in liver 
function and patient and graft survival. However, several clinical and experimental studies 
have shown an advantage for liver allografts rearterialized before portal reperfusion 173 387 388 
389 In this study we investigated the impact of the timing of rearterialization in liver 
transplantation using more sensitive parameters of injury, including markers of hepatocellular 
injury, reperfusion injury and endothelial cell function . 
In this study liver allografts rearterialized 20 minutes after portal reperfusion (PV-20-HA), 
which represents a standard uncomplicated transplant, were compared with rearterialization 
60 minutes after portal reperfusion (PV-60-HA), which represents the difficult hepatic artery 
dissection, and rearterialization simultaneous with (HA-PV) or prior to (HA-20-PV) portal 
reperfusion , representing the new trend in clinical liver transplantation. 
All transplanted livers undergo preservation-reperfusion injury. The pathophysiology involved 
in this preservation-reperfusion injury and possible preventative modalities have been 
extensively reviewed 66• The effect of the timing of rearterialization of the liver allograft on the 
reperfusion injury has not been documented previously. The reperfusion injury is known to be 
mediated, at least in part, by the formation of reactive oxygen metabolites, which damage a 
spectrum of bio-molecules found in tissues, including membrane lipids. Peroxidation of these 
membrane lipids results in the formation of malondialhyde, which can thus be used as a 
marker of reperfusion injury. Vitamin A is a potent endogenous scavenger of reactive oxygen 
metabolites, and can also be used as a parameter of the reperfusion injury. 
In this study, there was a marked increase in MDA levels after portal reperfusion in the 
animals which received arterial blood after or simultaneous with portal reperfusion . In the 
animals which received arterial blood before portal reperfusion , MDA levels remained 
unchanged. This indicates that, using MDA as an indicator, there was no detectable 
reperfusion injury associated with portal reperfusion in the animals which received arterial 
blood before portal reperfusion . 
This abrogation of the reperfusion injury by early arterialization was confirmed by the vitamin 
A levels remaining elevated in the animals which received arterial blood before portal 
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reperfusion . The nearly identical patterns of vitamin A levels in group 3 and 4 add further 
support for the theory that primarily portal reperfusion is responsible for reperfusion injury, 
rather than arterial reperfusion . The decrease in vitamin A levels in the animals with portal 
reperfusion before arterialization also confirmed the reperfusion injury in these animals. 
Interestingly, there appeared to be evidence of reperfusion injury after portal reperfusion but 
not after arterialization. This may be related to the difference in the oxygen content between 
the arterial and portal blood. Although the arterial blood has a higher oxygen content, the 
major part of the total oxygen delivery to the liver is from the portal vein 455 . 
Serum AST levels were the highest in group 1 , indicating that delayed arterial reperfusion 
resulted in a significant increase of hepato-cellular damage. 
Hyaluronic acid (Ha) is removed primarily by hepatic endothelial cells 459• Increased Ha levels 
have been demonstrated in several types of liver disease 460. Since hepatic endothelial cell 
dysfunction is associated with increased Ha levels, Ha is considered to be a potential marker 
of hepatic endothelial cell function . In this study, there were no statistical differences between 
Ha levels of the four groups. 
Conclusion 
This study showed that early arterialization prior to portal reperfusion after liver 
transplantation was associated with less reperfusion injury and less hepatocellular injury. 
There was no demonstrable effect of earlier HA revascularization on endothelial dysfunction. 
These findings would support previous suggestions that in liver transplantation , the allograft 
should be rearterialized before portal reperfusion . 
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CHAPTER6 
Histological Assessment After Different 
Methods of Reperfusion after Liver 
Transplantation 
Summary 
Preservation - reperfusion injury is a major cause for graft failure after liver transplantation. 
This injury refers to a variety of insults after reperfusion of the graft, independent from 
technical errors, vascular problems, immunological reactions or infection. Significant injuries 
occur during the period of cold preservation. Loss of sinusoidal endothelial attachments to the 
underlying extracellular matrix results in loss of the normal antithrombogenic milieu . 
Reperfusion with recipient blood results in platelet aggregation and neutrophil sludging in all 
areas of denudation, preventing adequate reoxygenation . Early histopathological findings in 
biopsy specimens can predict poor graft outcome. The aim of this study is to analyze the 
effect of early rearterialization on histological findings of the liver biopsies after liver 
transplantation. 
Twenty young Large White X Landrace pigs ( weight 22-28 kg) were subjected to orthototopic 
liver transplantation. Livers were stored in Eurocollins solution for three hours on ice and the 
animals were randomized in four different groups of increasing earlier arterialization. Groups 
were aligned from delayed rearterialization (group 1) to early rearterialization (group 4 ), 
Biopsies were taken before and after cold storage, as well as 1 hour post transplantation. 
Results show that both hepatocyte vacuolization and neutrophil infiltration were significantly 
reduced in group 4 (early rearterialization) , as compared to group 1, 2 and 3. 
Single cell necrosis and group cell necrosis of the hepatocytes were both significantly 
reduced in group 3 and 4 as compared to group 1 and 2 (early venous reperfusion) . 
In this study it is demonstrated that an early rearterialization is associated with a decrease in 
early histopathological changes in the transplanted liver, indicating a lesser amount of primary 
dysfunction at a later state. 
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Introduction 
The majority of allografts which fail early after liver transplantation are due to preservation -
reperfusion injury, vascular thrombosis, humeral rejection or a combination of these 
461 462 463
. 
Preservation - reperfusion injury refers to a variety of pathological processes resulting in 
allograft dysfunction that begin immediately after transplantation and are not readily explained 
on the basis of a technical or vascular problem, alloimmunological reaction or infection 
458 464 
465 466 467 
Clinical and experimental animal studies show that one of the most significant injuries occurs 
during the period of cold preservation, when the donor organ is stored in a physiologically 
compatible preservation solution 
66 468 469
. Loss of sinusoidal endothelial attachments to the 
underlying extracellular matrix results in loss of the normal antithrombogenic milieu. 
Reperfusion with recipient blood results in platelet aggregation and neutrophil sludging in all 
areas of denudation. Microvascular thrombosis and localized activation of neutrophils with 
release of oxidative enzymes act together to diminish bloodflow and prevent adequate 
reoxygenation . 
It is well known that routine histopathological findings in biopsy specimens taken within hours 
after completed revascularization can, with reasonable accuracy, predict poor allograft 
function during the first few postoperative weeks 
464 465
. 
Specific indicators of severe preservation injury and reperfusion injury include zonal or 
confluent coagulative necrosis, particularly if it is periportal or bridging, and severe 
neutrophilic exudation 464
 465 466 467
. The subscapsular parenchyma is the most susceptible to 
damage in the peri-operative period 470. 
Histopathological changes of less severe hepatic cellular ischemic injury, usually reversible, 
include microvesicular steatosis and hepatocellular cytoaggregation. Cytoaggregation is a 
reversible form of cell injury manifest morphologically by a "rounding-up" of the hepatocytes, 
so that the cell assumes a rounded appearance instead of the normal polygonal configuration. 
The aim of this study is to assess the impact of early rearterialization on the histology of open 
liver biopsies after liver transplantation . 
Materials and Methods 
Twenty young Large White X Landrace pigs ( weight 22-28 kg) were subjected to orthototopic 
liver transplantation. Intravenous Sodium Thiopentone was used for induction of the 
anaesthesia, while anaesthesia was maintained with nitrous oxide and oxygen administered 
through an endotracheal tube. 
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Donor operation: A midline laparotomy was performed and the liver mobilized , starting from 
the suprahepatic inferior vena cava downwards, followed by hilar dissection and dissection of 
the infrahepatic inferior vena cava. After this dissection the first liver biopsy was taken. All 
liver biopsies were taken as a 1 cm by 1 cm wedge from the anterior border of the right lobe 
of the liver. The liver surface was secured with chromic catgut (2.0). The liver was than 
flushed with ice-cold Eurocollins Solution through the portal vein. Flushing was continued on 
the backtable, where both the hepatic artery and the bile duct were flushed . 
Storage: The donor livers were placed in a plastic container with Eurocollins solution and 
stored for three hours on ice. After this storage period the second liver biopsy was taken . 
Recipient operation: The animals were randomized in four different groups of increasing 
earlier arterialization. In group 1 the hepatic artery was perfused only one hour after portal 
vein perfusion, while in group 2 the hepatic artery was perfused 20 minutes after portal vein 
perfusion. In group 3 the hepatic artery was reperfused simultaneously with the portal vein, 
while in group 4 the hepatic artery was perfused initially, 20 minutes before the portal vein 
perfusion. The third liver biopsy was taken 1 hour after completed revascularization . 
Technique: Tissues were fixed in a buffered 10% formalin solution. Following fixing the 
specimens were processed automatically in a tissue processor overnight , through alcohol 
70%, 96% and absolute alcohol , xylol to paraffin wax. The tissues were then embedded in 
paraffin wax for cutting. Sections were cut with the aid of a microtome 2 micrometer thick, 
floated onto glass slides and fixed onto the slide with aid of heat (55-60 degrees Celsius). The 
sections were stained using Mayer's haematoxylin eosin method 471 . 
The sections of the liver were assessed for the following features: 1. Hepatocyte 
vacuolization; 2. Single cell necrosis of the hepatocytes; 3. Group cell necrosis of the 
hepatocytes; 4. Infiltration of neutrophils. Morphometric analysis of the histological indicators 
was performed on a semi-quantitative assessment of changes based on a score from O to 5, 
in which zero represents normal tissue, and the score increases gradually from 1 
(representing minimal changes) to 5 (representing severe alteration from normal tissue). All 
sections were assessed blindly by two independent pathologists with experience in the 
transplantation field . 
All statistics were calculated according to the method of the least significance difference 
(General ANOVA) as decribed by George Snedecor and William Cochran 472. 
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Results 
Results of the hepatic biopsies at base, post storage and one hour after full revascularization 
are shown. 
The results of hepatocyte vacuolization are shown in figure 6.1 . The mean value of the five 
animals is shown in each group. Hepatocyte vacuolization appeared to be the highest in 
group 2 and 3, while it was the lowest in group 4. Vacuolization was less in group 1, 
compared to group 2 and 3, but more than group 4. This difference was significant (p<0.03). 
A typical example of hepatocyte vacuolization is shown in picture 6.1 (Original magnification 
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I-+- group 1 -a- group 2 group 3 --group 41 
Mean hepatocyte vacuolization after liver transplantation in the four groups in 
a semi-quantitative score from Oto 5. 
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Picture 6.1 Hepatocyte vacuolization . Original magnification 1 OOX. 
Picture 6.2 Hepatocyte vacuolization . Original magnification 400X. 
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Single cell necrosis is shown in figure 6.2. In group 1 single hepatocyte cell necrosis was the 
highest, followed by group 2. Single cell necrosis was significantly less in group 3 and 4 
compared to group 1 and 2 (p<0.001). There was also a statistical difference between group 3 
and 4 (p<0.05). 
A typical example of hepatocyte cell necrosis can be seen in picture 6.3 (original 
magnification 200)() and picture 6.4 (original magnification 400)() . 
3 
Figure 6.2 
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Picture 6.3 Single cell necrosis of hepatocytes. Original magnification 200X. 
Picture 6.4 Single cell necrosis of hepatocytes. Original magnification 400X. 
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Group cell necrosis of hepatocytes is demonstrated in figure 6.3. Again , necrosis is the 
highest in group 1, followed by group 2, while there is minimal group cell necrosis in group 3 
and 4. The difference between the groups was statistically significant (p<0.001). 
A typical example of group cell necrosis can be seen in picture 6.5 (original magnification 
200X) and picture 6.6 (original magnification 400X). 
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Figure 6.3 Mean group cell necrosis in the four groups after liver transplantation in a 
semi-quantitative score. 
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Picture 6.5 Group cell necrosis of hepatocytes. Original magnification 200X. 
Picture 6.6 Group cell necrosis of hepatocytes. Original magnification 400X. 
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Infiltration of the hepatic tissue with neutrophils is demonstrated in figure 6.4. Infiltration of 
neutrophils was significantly raised after transplantation in group 1, 2 and 3 (p<0.005, p<0.02 
and p<0.02), but remained low in group 4. 
A typical example of neutrophil infiltration is shown in picture 6.7 (original magnification 200)() 
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Mean neutrophil infiltration after liver transplantation in the four groups in a 
semi-quantitative score. 
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Picture 6.7 Neutrophil infiltration in the transplanted liver. Original magnification 200X. 
Picture 6.8 Neutrophil infiltration in the transplanted liver. Original magnification 400X. 
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Discussion 
In normal liver transplantation, arterialization of the hepatic artery takes place after portal 
venous reperfusion. This leads to variable intervals between the reperfusion of the two 
vessels, dependent on the sometimes technically difficult arterial anastomosis 385 386. 
Recently, there are various reports of the advantage of early rearterialization of the liver after 
orthotopic liver allograft 387 388 389. Although there are several publications looking at a variety 
of biochemical indicators and clinical factors, there has been no objective histological 
measurements. 
In this study we looked specifically at the histopathology of transplanted livers after various 
modes of reperfusion . Early rearterialization was associated with less histological evidence of 
injury in all four categories looked at. In fact, our results show a correlation between the 
degree of injury and the time of rearterialization. 
As indicated earlier by Kakizoe and Yanaga 458, most animal models evaluating preservation -
reperfusion injury allow a precisely controlled analysis but ignore the contribution of the 
arterial blood flow and the metabolic derangements caused by a poorly functioning native 
liver. In humans, arterial flow plays a more vital role. The time sequence between reperfusion 
of the venous and arterial systems may vary considerably, particularly when difficulties are 
encountered with the arterial anastomosis or when an arterial graft has to be used. During this 
time, the liver is reperfused and warmed by relatively hypoxic , endotoxemic portal blood, 
which may contribute to an extension of the preservation - reperfusion injury. 
Conclusion 
It is clearly demonstrated that an early rearterialization is associated with a decrease in early 
histopathological changes in the native liver. 
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CHAPTER 7 
The Effect of Celsior, Wisconsin and Eurocollins 
Solution on the Hepatocellular, Reperfusion and 
Endothelial Cell Injury after Porcine Liver 
Transplantation 
Summary 
Initially, preservation solutions were developed to maintain cell function of the transplanted 
organs. However, recently developed preservation solutions also contain a variety of 
substances to reduce the reperfusion injury. In this study, we investigated the effect of three 
different preservation solutions, on the liver cell injury, endothelial cell function and 
reperfusion injury after liver transplantation . 
Large White X Landrace pigs of either sex were subjected to orthotopic liver transplantation . 
Donor livers were flushed and stored in University of Wisconsin Solution (UW}, Eurocollins 
Solution (EU) or Celsior Solution (CEL) for 3 hours. Blood samples were taken at various 
times post transplantation for assessment of aspartate aminotransferase (AST), hyaluronic 
acid (Ha} , malondialdehyde (MDA) and Vitamin A (Vit A) levels. 
Serum AST levels were lower in the livers preserved in the UW solution. Plasma MDA levels 
were lower and serum Vit A levels were higher in the livers preserved in CEL solution. Serum 
HA levels increased after liver transplantation but were similar with all three solutions. 
These studies show that there was less hepatocellular injury in the livers preserved in UW 
Solution and less reperfusion injury with the CEL solution. The endothelial cell injury was 
similar with all three solutions. 
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Introduction 
Clinical liver transplantation is now performed routinely in the treatment of end-stage liver 
disease. Although much progress has been made in the field of organ preservation, it remains 
a popular topic of research, as a result of the increasing demand for better-functioning donor 
organs. 
In 1969 Collins described a cold storage solution for kidney preservation 95 • This solution was 
used initially in clinical liver transplantation as well, with preservation times limited to 6-8 
hours. The University of Wisconsin solution WcJ~ i~troduced into clinical liver transplantation in 
the 1980's and resulted in not only an extension'· of the preservation time to 18-24 hours but 
J 
also an improvement in the quality of the donor organ. Celsior was originally developed as a 
cardioplegic and cardiac preservation solution. Recently efforts have been made to establish 
Celsior as a liver and kidney preservation solution. One of the advantages of Celsior would 
be that a single solution could be used for the preservation of all organs. 
It is becoming increasingly apparent that the preservation of the liver is extremely complex 
and involves many forms of injury, besides ischaemia, to both parenchymal and non-
parenchymal cells. Thus new preservation solutions not only have to prolong the duration of 
preservation and improve the quality of preservation; but should also modify the various types 
of injury. In this study, we investigated the effect of UW solution, Celsior and Eurocollins 
solution on the hepatocellular injury, reperfusion injury and endothelial cell injury after liver 
transplantation. 
. ... 
Materials and Methods 
The study was approved by the University of Cape Town Animal Research Review 
Committee. 15 Large White X Landrace pigs weighing 20-30kg were anaesthetized with 
intravenous thiopentone sodium (2mg/kg) and anaesthesia maintained with nitrous oxide and 
oxygen delivered via an endotracheal tube. Catheters (Fr8) were inserted into the internal 
jugular vein for the infusion of intravenous fluids and into the carotid artery for blood sampling 
and blood pressure monitoring. The abdomen was explored via a midline incision extending 
from the xiphisternum to the symphysis pubis. 
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Donor Operation 
The ligaments attached to the liver were divided and the porta hepatis dissected to isolate the 
portal vein , hepatic artery and bile duct. The supra- and infra-hepatic vena cavae were also 
isolated. At this stage the animals were heparinized and a perfusion cannula placed in the 
portal vein . The vessels were clamped and the liver perfused in situ with ice-cold 
preservation solution (according to the randomization below) via the portal vein . The liver 
was excised and perfusion with ice-cold preservation solution continued ex situ via the portal 
vein , hepatic artery and bile duct. The portal vein was perfused with 700 ml, the hepatic artery 
with 200 ml and the bileduct with 100 ml of the particular solution. Thereafter the liver was 
secured in a plastic bag with the remaining cold storage solution and stored on ice for three 
hours. 
Preservation Solution 
The donor livers were randomly allocated to the following treatment groups, and perfused and 
preserved as follows: 
Group 1 (n=S): 
Group 2 (n=4): 
Group 3 (n=6): 
Eurocollins solution 
University of Wisconsin solution (UW) 
Celsior solution 
All livers were preserved for three hours prior to transplantation. 
Recipient Operation 
The preparation of the recipient liver was similar to the donor liver as described above. After 
heparinization, the non-pulsatile veno-venous bypass from the splenic vein to the external 
jugular vein was established. The bile duct was divided, the vessels clamped and the 
recipient liver excised. 
Implantation of the donor liver was achieved by anastomosing the suprahepatic vena cava, 
the infrahepatic vena cava and the portal vein . These vessels were unclamped and the liver 
perfused with portal blood. Thereafter the hepatic arterial anastomosis was completed. 
Finally, the biliary anastomosis was performed and the veno-venous bypass removed. 
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postoperatively. The blood samples were used to evaluate the serum AST, plasma 
malondialdehyde, serum vitamin A and serum hyaluronic acid levels. 
Sampling and Assays 
Blood samples were taken at various time intervals. From previous studies it has been shown 
that the first hour is the most sensitive to alterations in reperfusion injury markers. The 
reperfusion injury markers (Malondialdehyde and Vitamin A) were measured at base, before 
portal reperfusion (pre-port) , after portal reperfusion (post-port) , before arterial reperfusion 
(pre-art) , after arterial reperfusion (post-art) and 5, 20, 40 and 60 minutes after completed 
reperfusion . Hepatocellular injury related to reperfusion injury was determined in the first 24 
hours. Blood samples were taken preoperatively and at 1 hour, 2 hours and 4 hours post 
transplantation for analysis of the hepatocellular injury marker, serum AST. 
The marker for endothelial cell function , serum hyaluronic acid, was also measured in the first 
hour (at base, at 5 and 60 minutes post reperfusion) , which is the most crucial time for the 
endothelial cell function post reperfusion . 
Plasma Malondialdehyde (MDA) levels were determined by the thiobarbituric assay as 
described by Lepage 
452
. 2-Thiobarbituric acid (TBA) was added to deproteinized plasma 
and the reaction between the MDA and TBA, under conditions of low pH and high 
temperature, yielded a chromogenic adduct that was detectable by fluorometry. 
Serum Vitamin A levels were measured fluorometrically, according to the original method 
described by Thompson 
453
. Vitamin A, which fluoresces in ultraviolet light, was first extracted 
into water and ethanol , than into hexane and detected by fluorometry. 
Serum Hyaluronic Acid (Ha) levels were estimated by radioimmunoassay using a kit 
purchased from Kabi Pharmacia 
454
. 125 I-labeled Hyaluronic Acid binding protein (HASP), 
isolated from bovine cartilage, was used to bind the Ha in the sample. The unbound 125 1-
HABP was quantitated by incubating with Ha covalently coupled to Sepharose particles. 
Separation is performed by centrifugation and decanting. The radioactivity bound to the 
particles is read in a gamma counter which is inversely proportional to the concentration of Ha 
in the sample. 




The changes in serum AST levels after liver transplantation in the three groups of animals are 
shown in Figure 7.1. There was a significant increase in serum AST levels after liver 
transplantation in all three groups.(p<0.001) Serum AST levels were lower on the second 
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Mean Serum AST levels after liver transplantation in the 3 groups in 
international units. 
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The changes in plasma malondialdehyde levels are shown in Figure 7.2. There was a 
significant increase in plasma MDA levels after portal reperfusion (p<0.04) in the animals with 
livers preserved in Eurocollins, Plasma MDA levels in the animals with UW preserved livers 
remained unchanged after liver transplantation. Plasma MDA levels were lowest in the 
recipients of livers stored in Celsior. Plasma MDA levels were back to baseline levels by 20 
minutes after transplantation. 
M DA after liver transplantation 
6 * 
0 +----~---~---~---~---~------------
base pre-portal post-portal pre -arterial 5 minutes 20 minutes 40 m inu tes 60 minutes 
Figure 7.2: 
1-+- Celsior --- Eurocollins _.._ UW j 
* p<0.04 
Arterial levels of Malondialdehyde during and after liver transplantation in 
µmol/1 . 
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The serum vitamin A levels, as shown in Figure 7.3, were highest in the Celsior group and 
lowest in the recipients of livers which were preserved in Eurocollins solution. There was a 
decrease in serum vitamin A levels after portal reperfusion in all three groups of animals, only 
the decrease in the Eurocollins group being statistically significant (p<0.04). 
\Atatin Aleuels ater liwr lYcn;pa tlaia1 
25 
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Figure 7.3 
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1-+- C.elsicr ..._ B.rox:ilins -.-LWj 
* p<0.04 
Arterial levels of Vitamin A at various times during and after liver 
transplantation in mg/I. 
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The changes in serum hyaluronic acid levels after liver transplantation are shown in Figure 
7.4. Serum Ha levels increased after transplantation in all three groups of animals. However, 
there was no difference in serum Ha levels between the groups of animals with different 
preservation solutions.(p<0.30) 
Figure 7.4 
Hyaluronic Acid levels after liver 
transplantation 
base 5 ninutes 
I-+- Celsior -+- Eurocollins -&- uwl 
60 ninutes 
Hepatic venous levels of hyaluronic acid after completion of liver 
transplantation in µg/1. 
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Discussion 
Improvements in the duration and quality of preservation of the livers for clinical 
transplantation are of paramount importance in order to both increase the number of 
transplants performed and the function of the donor organs. With Eurocollins solution 
preservation of the liver was limited to 6-8 hours of cold ischaemia. The introduction of the 
UW solution not only resulted in the extension of the preservation period beyond 24 hours, 
but there was also an improvement in the function of the liver allografl. Celsior has been 
used as a cardioplegic and cardiac preservation solution in the past. The use of Celsior as a 
liver preservation solution has not been documented previously. 
These preservation solutions contain many substances and the importance of each of the 
individual constituents for simple cold storage is sometimes not clear. The UW solution 
contains lactobionate and raffinose as impermeants to suppress hypothermia-induced cell 
swelling, reduced glutathione as an antioxidant, adenosine as a precursor for synthesis of 
adenine nucleotides, allopurinol as a free radical scavenger, and hydroxyethyl starch as a 
colloid for oncotic support. Celsior is similar to UW solution in that it contains lactobionate as 
an impermeant and reduced glutathione as an antioxidant. However, Celsior also contains 
mannitol because of its dual capacity to behave as an osmotic agent and a free radical 
scavenger, histidine for its buffering properties, and glutamic acid for its capacity to yield ATP. 
It is becoming increasingly apparent that the preservation of organs for clinical transplantation 
using simple cold storage is complex and involves more than the prevention of the anoxic 
damage to the parenchymal cells. For example, the reperfusion injury may be responsible for 
a greater amount of damage than the anoxic injury 66. There is also a difference in the 
susceptibility of the different types of cells in the liver to the various forms of injury 179. 
The pathophysiology involved in the preservation-reperfusion injury has been extensively 
documented 76. Reactive oxygen metabolites are responsible for the reperfusion injury by 
damaging a spectrum of bio-molecules found in tissues, including membrane lipids. 
Peroxidation of these membrane lipids results in the formation of malondialdehyde. The level 
of MDA in the blood correlates with the degree of reperfusion injury. Vitamin A is a potent 
endogenous scavenger of reactive oxygen metabolites and serum vitamin A levels are also 
an indication of the extent of the reperfusion injury. 
One of the particular problems in this study are the small numbers, making it difficult to reach 
statistical differences between the groups. The reason for the small number of animals used 
was cost-saving. 
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The plasma MDA levels after portal reperfusion in this study were the highest in the animals 
with livers preserved in Eurocollins solution and lowest in the animals with livers preserved in 
Celsior. Similarly, serum vitamin A levels were the highest in the Celsior animals and lowest 
in the Eurocollins group. Thus, there appears to be the greatest amount of reperfusion injury 
in Eurocollins group and the least in the Celsior group. 
The serum AST levels were used as a marker of hepatocyte injury. Serum AST levels on day 
2 postoperatively, were the lowest in the animals with livers preserved with UW. Serum AST 
levels were similar in the Celsior and Eurocollins groups of animals. Thus, the least amount 
of hepatocyte injury was found in the animals with livers preserved with UW solution. 
New refinements in preservation solutions will have to address the effect of the preservation-
ischaemia-reperfusion injury on other non-parenchymal cell-types. For example, significant 
hepatic endothelial cell dysfunction may have a significant impact on the outcome and 
incidence of septic complications after liver transplantation. The effect of the different 
preservation solutions on hepatic endothelial cell function has not been documented 
previously. Hyaluronic acid (Ha) is removed primarily by hepatic endothelial cells and an 
increase in Ha levels is associated with hepatic endothelial cell dysfunction. Thus, in this 
study, Ha was used as a marker of endothelial cell function . There was a significant increase 
in Ha levels after liver transplantation, indicating marked endothelial cell dysfunction. This 
injury was not modified by any of the preservation solutions. 
In future, new preservation solutions will have to be evaluated not only by its ability to prolong 
preservation time and improve survival, but also by its effect on the various types of cell injury. 
For example, both UW solution and Celsior contain antioxidants and free radical scavengers 
to minimize the reperfusion injury. 
Conclusion 
Livers preserved in UW solution had less hepatocellular injury and more reperfusion injury 
compared to those preserved in Celsior. The degree of endothelial cell injury was similar in 




This thesis was primarily directed at defining new methods to decrease the preservation 
reperfusion injury after orthotopic liver transplantation. 
1. There is a significant reperfusion injury associated with portal venous revascularization 
(PV) during liver transplantation and not with hepatic arterial revascularization (HA). 
Furthermore, HA before PV prevented the reperfusion injury associated with PV. 
2. Delayed revascularization of the liver during liver transplantation was associated with 
significant reperfusion injury and hepatocellular injury. 
3. Early rearterialization of the liver during liver transplantation prevented the reperfusion 
injury and was associated with less hepatocellular injury. 
4. Early rearterialization of the liver during transplantation was associated with histological 
evidence of less hepatocellular injury when compared to delayed rearterialization . 
5. The use of Celsior as a preservation solution in orthotopic liver transplantation was 
associated with a lesser reperfusion injury, but a greater hepatocellular injury, when 




ANOVA= Analysis of variance 
Df = Degrees of freedom 
Ms = Mean sqare 
F = f-statistic 
p-level = level of significance 
Analysis of variance tables 
All means were compared by the method of the least significance difference (General 
ANOVA) as decribed by George Snedecor and William Cochran 472 . 
ANOVA 1-group, 2-
time 
Effect Of Effect Ms Effect Of Error Ms Error F 
1 3 2.373362 77 6.137996 .386667 
2 4 1.231139 77 6.137996 .200577 
1&2 12 1.638839 77 6.137996 .266999 
Table 4.1 Malondialdehyde 
ANOVA 1-group, 2-
time 
Effect Df Effect Ms Effect Of Error Ms Error F 
1 3* 532.5300* 60* 75.64205* 7.040132* 
2 6 15.9746 60 75.64205 .211186 
1&2 18 33.2849 60 75.64205 .440031 
Table 4.2 Vitamin A 
ANOVA 1-group, 2-
time 
Effect Of Effect Ms Effect Of Error Ms Error F 
1 3* 71903.* 70* 21724.45* 3.30978* 
2 4* 1007649.* 70* 21724.45* 46.38315* 
1&2 12 31350. 70 21724.45 1.44308 
Table 4.3 Aspartate amino transferase 
ANOVA 1-group, 2-
time 
Effect Df Effect Ms Effect Df Error Ms Error F 
1 3 169395. 53 68228.64 2.48275 
2 4* 4576059.* 53* 68228.64* 67.06947* 
1&2 12 19412. 53 68228.64 .28452 
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Effect Df Effect Ms Effect Df Error Ms Error F 
1 3 .950000 48 .500000 1.90000 
2 2* 5.716667* 48* .500000* 11.43333* 
1&2 6 .450000 48 .500000 .90000 
Table 6.1 Hepatocyte vacuol ization 
ANOVA 1-group, 2-
time 
Effect Df Effect Ms Effect Df Error Ms Error F 
1 3* 1.30556* 48* .308333* 4.23423* 
2 2* 17.51667* 48* .308333* 56.81081 * 
1&2 6* .87222* 48* .308333* 2.82883* 
Table 6.2 Single cell necrosis 
ANOVA 1-group, 2-
time 
Effect Df Effect Ms Effect Df Error Ms Error F 
1 3* 1.444444* 48* .258333* 5.59140* 
2 2* 7.016667* 48* .258333* 27.16129* 
1&2 6* 1.194444* 48* .258333* 4.62366* 
Table 6.3 Group cell necrosis 
ANOVA 1-group, 2-
time 
Effect Df Effect Ms Effect Df Error Ms Error F 
1 3 .266667 48 .291667 .91429 
2 2* 6.650000* 48* .291667* 22.80000* 
1&2 6 .383333 48 .291667 1.31429 
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Effect Of Effect Ms Effect Of Error Ms Error F 
1 2 108430.3 33 49056.05 2.21033 
2 3* 901396.6* 33* 49056.05* 18.37483* 
1&2 6 81322.1 33 49056.05 1.65774 
Table 7.1 Aspartate aminotransferase 
ANOVA 1-group, 2-
time 
Effect Of Effect Ms Effect Of Error Ms Error F 
1 2 5.283679 88 6.442274 .820158 
2 7 3.618097 88 6.442274 .561618 
1&2 14 2.018104 88 6.442274 .313260 
Table 7.2 Malondialdehyde 
ANOVA 1-group, 2-
time 
Effect Of Effect Ms Effect Of Error Ms Error F 
1 2* 674.7001* 76* 58.04640* 11 .62346* 
2 7 78.6456 76 58.04640 1.35487 
1&2 14 16.4544 76 58.04640 .28347 
Table 7.3 Vitam in A 
ANOVA 1-group, 2-
time 
Effect Of Effect Ms Effect Of Error Ms Error F 
1 2 46052. 21 36112.97 1.2752 
2 2* 56369335.* 21 * 36112.97* 156.0917* 
1&2 4 367787. 21 36112.97 1.0187 
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